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Publiekssamenvatting
Seksueel overdraagbare aandoeningen, waaronder hiv, in Nederland in 2013
Het aantal mensen dat zich bij een Centrum Seksuele Gezondheid heeft laten testen op een 
seksueel overdraagbare aandoening (soa) is verder gestegen in 2013. Het percentage mensen 
met een soa is voor het eerst licht gedaald (met 0,4 procent) sinds 2007. Desondanks blijft 
dit percentage hoog (14,7 procent). Een goed functionerende soa-monitoring blijft daarom 
essentieel om zicht te houden op relevante trends, opkomende soa binnen groepen die een 
grotere kans hebben er een op te lopen, en de effectiviteit van preventieprogramma’s. 
De Centra Seksuele Gezondheid (CSG), voorheen soa-poli’s, bieden hoogrisicogroepen de 
mogelijkheid om zich gratis te laten testen op soa en verstrekken medicatie als er een wordt 
vastgesteld. Het totaal aantal consulten in 2013 bedroeg 133.585 en is met 10 procent toegenomen 
ten opzichte van 2012. Van alle bezoekers werden de meeste soa gediagnosticeerd bij mensen die 
ervoor gewaarschuwd waren dat ze mogelijk een soa hadden opgelopen, mensen jonger dan 25 
jaar, migranten uit gebieden waar soa en hiv veel voorkomen (bijvoorbeeld Afrika, Zuid-Amerika 
of Oost-Europa), of mannen die seks hebben met mannen (MSM). 
Chlamydia
Net als in voorgaande jaren was chlamydia de meest gediagnosticeerde soa bij de CSG in 2013 
(15.767 diagnoses). Het percentage mensen dat chlamydia had, daalde licht ten opzichte van 2012 
(van 12,2 naar 11,8 procent). Chlamydia werd het meest vastgesteld bij heteroseksuelen, zowel 
mannen als vrouwen, onder de 25 jaar. Na de uitschieter in 2012 van het aantal en percentage 
mensen met een agressieve variant van chlamydia, lymphogranuloma venereum, zijn deze cijfers 
weer afgenomen naar het niveau van de jaren daarvoor (7 procent in 2013). 
Gonorroe
Het percentage personen met een gonorroe-infectie bij de CSG bleef in 2013 stabiel ten opzichte 
van 2012 (3,6 procent in 2012 en 3,4 procent in 2013), nadat het in de voorgaande jaren licht was 
gestegen. Deze soa werd het meest gediagnosticeerd bij MSM. Het blijft belangrijk om te volgen 
of de gonorroe-bacterie resistent raakt tegen de antibiotica die in Nederland voorgeschreven 
worden, de zogenoemde derde generatie cefalosporines. In diverse Europese landen is deze 
resistentie waargenomen.
Hiv
Het aantal personen met een hiv-infectie, gediagnosticeerd bij een van de CSG, is in 2013 gelijk 
gebleven ten opzichte van 2012 (358 versus 356 in 2012). Het percentage positieve testen daalt 
sinds 2008: van 3,0 procent naar 1,4 procent bij MSM in 2013. Het percentage mensen dat in een 
laat stadium van een hiv-infectie bij een hiv-behandelcentrum komt, is de afgelopen jaren gedaald. 
Het is van belang om tijdig de hiv-diagnose te stellen en zo snel mogelijk de behandeling te starten, 
omdat hierdoor de gezondheidsschade bij de patiënt verkleind kan worden. Ook neemt door 
behandeling de besmettelijkheid af, waardoor de kans kleiner is dat hiv wordt overgedragen. 
Trefwoorden: soa, MSM, chlamydia, gonorroe, hiv, resistentie, jongeren, monitoring, centrum 
seksuele gezondheid
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Abstract
Sexually transmitted infections, including HIV, in the Netherlands in 2013
In 2013, more people were tested for sexually transmitted infections (STI) at Dutch STI 
clinics than in previous years. Although the percentage of people with an STI showed a 
slight decrease (0.4 per cent) for the first time since 2007, it remained high at 14.7 per cent. 
Effective STI monitoring remains essential for the identification of relevant trends, 
emerging STIs in high-risk groups, and the effectiveness of prevention programmes. 
STI clinics offer high-risk groups access to free testing for STI and provide care and treatment if 
an STI is diagnosed. The total number of consultations in 2013 was 133,585, an increase of 10% 
compared with 2012. In 2013, STI clinic attendees with an STI were mainly people who reported 
having been notified of their possible exposure to STI, people aged 20-24, people originating 
from areas in which STI/HIV is common (e.g. Africa, South America or Eastern Europe), and 
men who have sex with men (MSM). 
Chlamydia
With 15,767 cases, chlamydia remains the most commonly diagnosed STI in 2013. The percen-
tage of people diagnosed with chlamydia was slightly lower in 2013 than in 2012 (11.8 versus 
12.2 respectively). Chlamydia was primarily diagnosed in heterosexuals younger than 25 years 
old and in both men and women. Following the increase in the number and percentage of 
lymphogranuloma venereum (LGV; an aggressive variant of chlamydia) infections in 2012, 
these numbers declined to a level comparable to previous years in 2013.
Gonorrhoea
Whereas the percentage of people with a gonorrhoea infection slightly had increased in 
previous years, the percentage remained stable in 2013 (3.4 per cent) compared with 2012 (3.6 
per cent). Gonorrhoea was mostly diagnosed in MSM. It remains important to monitor the 
resistance of the gonorrhoea bacteria against the antibiotic currently recommended in the 
Netherlands, a third-generation cephalosporin. A rising rate of resistance to this antibiotic has 
been observed in several European countries. 
HIV
The number of people diagnosed with HIV at STI clinics in 2013 was similar to that of 2012 (358 
versus 356 respectively). Among MSM, the percentage of positive HIV tests decreased from 3.0 
per cent in 2008 to 1.4 per cent in 2013. The percentage of HIV-positive people who were 
diagnosed at a late stage of the infection has decreased in previous years. Early diagnosis and 
treatment of an HIV infection is important because of individual health benefits and the 
potential reduction of HIV transmission.
Keywords: STI, MSM, chlamydia, gonorrhoea, HIV, resistance, youth, monitoring, STI clinic 
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Preface
This annual report presents the national surveillance data and a review of the epidemiology of 
sexually transmitted infections (STI), including HIV/AIDS, in the Netherlands in 2013. The report 
provides an overview of recent trends and current developments in the field of STI. This is 
done by presenting a summary of recent trends (‘key points’) followed by tabulations and 
figures relating to STI analysed in relation to a range of relevant characteristics and risk groups 
over time from available data sources and an overview of the major discussions and 
recommendations.  
We hope that this report will contribute to further awareness of the distribution and factors 
influencing the spread of STI, including HIV, in the Netherlands, resulting in development and 
targeting of (preventive) interventions and enable assessment of the effectiveness of control 
activities on STI transmission. The information aims to support policy makers and researchers 
in the field of STI and related subjects as well as others interested in STI trends in the 
Netherlands. More information on STI and HIV trends in the Netherlands is available at www.
soahiv.nl and www.hiv-monitoring.nl. A copy of this report can also be downloaded in PDF 
format from www.soahiv.nl.
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Samenvatting
In 2013 werden in totaal 133.585 soa-consulten uitgevoerd bij de Centra Seksuele Gezondheid 
(CSG), een stijging van 10 procent ten opzichte van 2012. Hoewel licht gedaald van 15,1 procent 
in 2012 naar 14,7 procent in 2013, blijft het percentage bezoekers dat gediagnosticeerd is met 
één of meer soa (chlamydia, gonorroe, infectieuze syfilis, hepatitis B of hiv) hoog. De CSG zijn 
bedoeld voor hoogrisicogroepen die in de reguliere zorg niet voldoende bereikt worden. Om 
deze groepen te bereiken passen de CSG een landelijk afgestemd triagesysteem toe. De 
hoogrisicogroepen - waaronder mannen die seks hebben met mannen (MSM) (21 procent van 
de bezoekers in 2013), personen afkomstig uit soa/hiv endemische gebieden (25 procent van 
de bezoekers in 2013) en jongeren tot 25 jaar (49 procent van de bezoekers in 2013) - worden 
gratis getest. In 2013 voldeed 99 procent van de soa-consulten aan minimaal een van de 
gestelde criteria voor hoogrisicogroepen. 
Huisartsendata laat zien dat het totaal aantal soa-diagnoses en soa-gerelateerde episodes die 
bij de huisarts worden vastgesteld veel groter is dan het aantal bij de CSG. De huisarts bereikt 
hoogrisicogroepen ook goed, zoals jongeren onder de 25 jaar en personen afkomstig uit soa/
hiv endemische gebieden, maar specifieke groepen zoals MSM en prostituees naar verhouding 
minder. Trends in huisartsendata per soa zijn beschikbaar tot 2012, maar door aanpassing 
(actualisering) van definities van episodes en aanpassing van de berekeningen van de preva-
lentie zijn vrijwel alle soa’s cijfermatig toegenomen.
Naast data van de CSG en huisartsen worden, waar beschikbaar, trenddata uit de reguliere 
zorg, zoals hiv-behandelaren en andere surveillance bronnen, gerapporteerd.
Bacteriële soa
In 2013 was chlamydia opnieuw de meest gediagnosticeerde bacteriële soa bij de CSG met 
15.767 gerapporteerde gevallen. Het percentage positieve testen daalde licht van 12,2 procent 
in 2012 naar 11,8 procent in 2013. De hoogste percentages positieve testen werden gezien 
onder heteroseksuele mannen en vrouwen (respectievelijk 12,8 en 12,2 procent). De meerder-
heid van de chlamydia-infecties werd bij jongeren onder de 25 jaar gediagnosticeerd (61 
procent). Lymphogranuloma venereum (LGV), een agressieve variant van chlamydia, was in 
2012 sterk toegenomen, maar is in 2013 weer gedaald; 6,7 procent was positief in 2013 versus 
13,1 procent in 2012. Het geschatte aantal chlamydia episodes bij de huisarts die berekend zijn 
met de nieuwe methode waren hoger dan de aantallen gerapporteerd in 2010 en 2011 op basis 
van de oude methode; waarschijnlijk door de verandering van definities en de berekening van 
de prevalentie. Het geschatte aantal chlamydia episodes bij de huisarts in 2012 was 273 per 
100.000 inwoners. 
Sinds 2008 werd bij zowel heteroseksuelen als MSM een toename gezien in het percentage 
positieve gonorroetesten bij de CSG. In 2013 bleef dit percentage stabiel (3,4 procent) ten 
opzichte van 2012 (3,6 procent). Gonorroe werd vooral gediagnosticeerd bij MSM: 9,3 procent 
testte positief (9,3 procent in 2012), vergeleken met 1,7 procent van de heteroseksuele mannen 
(2,1 procent in 2012) en 1,8 procent van de vrouwen (1,9 procent in 2012). Het geschatte aantal 
gonorroe-episodes bij de huisarts die berekend zijn met de nieuwe methode waren hoger dan 
wat in op basis van de oude methode werd geschat in 2010 en 2011. Het geschatte aantal 
gonorroe episodes bij de huisarts was 50 per 100.000 inwoners in 2012. Monitoring van antibioti-
caresistentie bij gonorroe blijft van belang, zeker gezien de gerapporteerde resistentie tegen 
derde generatie cefalosporines in Europa. In Nederland is dat tot nu toe nog niet het geval.
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Het percentage positieve testen van infectieuze syfilis bij MSM (2,1 procent) in 2013 lijkt na 
jaren van daling (van 4,3 procent in 2007 naar 2,0 procent in 2011) te stabiliseren bij de CSG. In 
totaal werden er in 2013 626 infectieuze syfilis diagnoses vastgesteld, waarvan 93 procent bij 
MSM.
Virale soa, inclusief hiv
Bij de CSG werden 356 nieuwe hiv-diagnoses vastgesteld in 2013. Het percentage positieve 
hiv-testen voor MSM neemt sinds 2008 af: van 3,0 procent in 2008 naar 1,4 procent in 2013. Bij 
heteroseksuele mannen en vrouwen bleef dit percentage lager dan 0,1 procent. Bij 25,4 
procent van de nieuw gediagnosticeerde hiv-positieve MSM die de CSG bezochten werd ook 
een chlamydia-infectie gevonden en bij 19,7 procent een gonorroe-infectie.
In 2013 werden 1.175 nieuwe aanmeldingen van hiv-positieve personen in zorg gerapporteerd 
in de nationale hiv-registratie bij de Stichting HIV Monitoring, waarvan er 829 ook gediagnos-
ticeerd waren in 2013. Eind 2013 waren in totaal 21.858 personen met hiv in Nederland geregi-
streerd. Van alle nieuw geregistreerde hiv-patiënten was 70 procent MSM en 23 procent 
heteroseksueel. 
Van alle hiv-positieve MSM geregistreerd in zorg, zijn de meesten gediagnosticeerd bij een van 
de CSG (38 procent). Hiv-positieve heteroseksuele mannen en vrouwen geregistreerd in zorg, 
werden echter vaker in een ziekenhuis gediagnosticeerd (respectievelijk 50 en 49 procent). De 
huisarts diagnosticeerde ongeveer een derde van hen (31% van de MSM, 40% van de hetero-
seksuele mannen en 23% van de vrouwen).
Het aandeel personen met hiv dat laat in zorg kwam (<350 CD4 cellen/mm3) is de laatste jaren 
gedaald, maar bleef in 2013 stabiel ten opzichte van 2012 (43 procent). Dit percentage was het 
laagst voor MSM (34 procent); bij heteroseksuelen was dit 62 procent. Het percentage perso-
nen dat laat in zorg komt is hoger bij diegenen die gediagnosticeerd zijn in het ziekenhuis (66 
procent) of bij de huisarts (41 procent) dan diegenen die gediagnosticeerd zijn bij een van de 
CSG (26 procent).
Het aantal diagnoses van genitale wratten bij de CSG nam in 2013 af met 11 procent naar 2.057. 
Het percentage positieve testen nam af van 2,9 procent in 2009 naar 1,5 procent in 2013. Het 
aantal diagnoses en het percentage positieve testen van genitale herpes (HSV) in 2013 (612; 0,5 
procent) was ongeveer gelijk aan 2012. Hierbij moet worden opgemerkt dat onderzoek naar 
genitale wratten en HSV alleen op indicatie gebeurt, waardoor het aantal diagnoses en het 
percentage positieve testen niet vergelijkbaar zijn met die van bacteriële soa en hiv, waarop 
routinematig getest wordt. Bij de huisarts is in de laatste jaren steeds een lichte stijging te zien 
in gerapporteerde diagnoses HSV en genitale wratten. Met de nieuwe methode om de 
prevalentie te berekenen zien we een veel grotere toename tussen 2011 en 2012, waarschijnlijk 
door het opsplitsen van episodes die voorheen als een langdurige episode werden geteld. Uit 
de aangiftecijfers van acute hepatitis B bleek dat in 2013 de incidentie 0,8 per 100.000 inwo-
ners was. Het aantal acute hepatitis B-infecties daalde met 23 procent in vergelijking met 2012 
naar 130 gevallen. Het aantal gerapporteerde acute hepatitis C-gevallen in de aangiftecijfers 
nam met 72 procent toe van 36 in 2012 tot 62 in 2013.
In het kort, het aantal soa-consulten blijft nog steeds jaarlijks toenemen. Terwijl in voorgaande 
jaren het percentage CSG-bezoekers waarbij een soa werd gevonden bleef toenemen, lijkt dit 
percentage zich in 2013 te stabiliseren. Een intensieve soa-surveillance blijft essentieel om zicht 
te houden op relevante trends. De bestrijding zou verder ondersteund kunnen worden door 
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het versterken van intersectorale samenwerking tussen de verschillende zorgverleners, het 
verder implementeren van richtlijnen, het continueren van de monitoring van opkomende soa 
en trends binnen hoogrisicogroepen, het bevorderen van partnerwaarschuwing, het zichtbaar 
maken van regionale verschillen, het integreren van soa-screening met HIV-zorg en het 
systematisch kweken van de gonorroe die wordt gevonden bij hoogrisicogroepen om over-
dracht van resistente stammen te voorkomen. 
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Summary
In 2013, 133,585 STI consultations were carried out at Dutch STI clinics, an increase of 10 
percent compared with 2012. Although the overall percentage of positive STI tests (chlamydia, 
gonorrhoea, infectious syphilis, hepatitis B or HIV) slightly decreased from 15.1 percent in 2012 
to 14.7 percent in 2013, this percentage remains high. STI clinics target high-risk groups by 
patient selection based on standardised criteria. High-risk groups, such as men having sex with 
men (MSM) (21 percent of all attendees in 2013), people originating from STI/HIV endemic 
areas (25 percent of all attendees in 2013) and people under 25 years of age (49 percent of all 
attendees in 2013), are tested free of charge. In 2013, 99 percent of attendees fulfilled one or 
more of the criteria for high-risk groups.
Data from general practices showed that the total number of STI diagnoses and STI related 
episodes registered is still much larger than the numbers reported from STI clinics. General 
practices reach high-risk groups like young people under 25 years and people originating from 
STI/HIV endemic areas quite well, but have a lesser reach to specific groups like MSM and 
prostitutes. Trends in general practice data per STI are available until 2012. However, adjust-
ments (updates) of definitions of episodes and calculations of prevalence rates caused an 
increase in nearly all STI numbers.
In addition to data from STI clinics and general practitioners, data from regular care like HIV 
treatment centres and other surveillance sources are also reported.
Bacterial STI
With 15,767 reported cases, chlamydia remained the most commonly diagnosed bacterial STI at 
STI clinics in 2013. The overall positivity rate was slightly lower in 2013 (11.8 per cent) than in 2012 
(12.2 percent). The highest positivity rates were found in heterosexual men and women (12.8 
percent and 12.2 percent respectively). The majority of chlamydia cases were diagnosed in people 
aged 24 years and younger (61 percent). After a remarkable increase in the percentage of 
lymphogranuloma venereum (LGV) infections, an aggressive variant of chlamydia, in 2012, the 
percentage of positive LGV tests decreased from 13.1 to 6.7 per cent in 2013. The estimated 
numbers of chlamydia episodes at general practitioners (GPs) using the new method were higher 
than the previous reported numbers in 2010 and 2011 using the old method, probably due to 
changes in definitions and calculations. In 2012, the estimated number of chlamydia episodes 
was 273 per 100,000 population. Between 2008 and 2012, the gonorrhoea positivity rate slightly 
increased at STI clinics each year. In 2013 however, the overall positivity rate for gonorrhoea 
remained stable compared to 2012 (3.6 per cent in 2012 and 3.4 per cent in 2013. Gonorrhoea was 
most prevalent among MSM: 9.3 percent tested positive (9.3 per cent in 2012), compared to 1.7 
percent (2.1 per cent in 2012) and 1.8 per cent (1.9 per cent in 2012) in heterosexual men and 
women respectively. Monitoring antimicrobial resistance in gonorrhoea remains important, 
especially given the reports of resistance against third-generation cephalosporins in Europe. So 
far, no resistance to ceftriaxone, a third-generation cephalosporin that has been the first-choice 
medication since 2004, has been found in the Netherlands. In general practice, the estimated 
number of gonorrhoea episodes using the new method was clearly higher than the reported 
estimates reported in 2010 and in 2011, both in men and in women. It is uncertain whether this 
increase is due to different definitions or due to true increased transmission. In 2012, the 
estimated number of gonorrhoea episodes was 50 per 100,000 population.
After years of decreasing positivity rates of infectious syphilis in MSM (from 4.3 percent in 2007 
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to 2.0 percent in 2011), the positivity rate (2.1 per cent) seems to have stabilised in 2013. In total, 
626 positive infectious syphilis tests were reported, of which 93 percent was diagnosed in MSM. 
Viral STI, including HIV
At STI clinics, 356 HIV infections were diagnosed in 2013. The HIV positivity rate among MSM 
continued to decrease; from 3.0 per cent in 2008 to 1.4 per cent in 2013. The positivity rate in 
heterosexual men and women remained lower than 0.1 percent. Of the newly diagnosed MSM 
at STI clinics, 25.4 per cent were co-infected with a chlamydia infection and 19.7 per cent were 
co-infected with a gonorrhoea infection.
In 2013, 1,175 HIV-infected people in care were newly registered in the national database of the 
HIV treatment centres (SHM); 829 of them were diagnosed in 2013. As of December 2013, 
21,858 HIV patients in medical care had been recorded in the Netherlands. The proportion of 
MSM among the newly registered was 70 per cent; 23 per cent were heterosexuals. 
Whereas HIV-positive MSM in care were mostly diagnosed at STI clinics (38 per cent), HIV-
positive heterosexual men and women in care were mostly diagnosed at hospitals (50 and 49 
per cent respectively). GPs diagnosed about one third of both groups (31% of MSM, 40% of 
heterosexual men and 23% of women). 
The percentage of HIV-positive people who were diagnosed at a late stage of the infection has 
decreased in previous years. Of patients diagnosed in 2013, 43 per cent were diagnosed late 
(<350 CD4 cell counts/mm3), which was stable compared with the percentage in 2012. This 
proportion was lower for MSM (34 per cent) than for heterosexuals (62 per cent). People who 
were diagnosed in hospitals or by GPs were more often diagnosed late (66 and 41 per cent) 
compared to people diagnosed at STI clinics (26 per cent).
At the STI clinics, the reported number of genital warts decreased by 11 per cent to 2,057. The 
percentage of positive tests decreased from 1.9 per cent in 2012 to 1.5 per cent in 2013. The 
number and the positivity rate of genital herpes (HSV) in 2013 (612; 0.5 per cent) was similar to 
2012. Since genital warts and HSV were tested by indication only, the number of diagnoses and 
the percentage testing positive are not comparable with the bacterial STI and HIV described 
above (routinely screened at all consultations). At GPs, the number of diagnoses of HSV and 
genital warts has increased gradually in recent years. As a result of the changes in definitions 
and calculations, we saw a much larger increase from 2011 to 2012, probably due to separating 
episodes which were previously counted as one episode. 
The notification data on acute hepatitis B showed an incidence of 0.8 per 100,000 inhabitants 
in 2013. The number of acute hepatitis B notifications decreased by 23 per cent to 130 cases in 
2013. The total number of reported acute hepatitis C cases increased from 36 cases in 2012 to 
62 in 2013.
In short, the number of STI consultations has increased since 2004. Whereas the overall STI 
positivity rate showed an increasing trend in previous years, the overall STI positivity rate in 
2013 was comparable with that of 2012. Strong STI surveillance remains essential to monitor 
relevant trends. STI control could be supported by strengthening  intersectional cooperation 
between the different care providers, implementation of guidelines, continued monitoring of 
emerging STI and trends for high-risk groups, strengthening partner notification, visualisation 
of regional differences, integration of STI screening into HIV care, and systematically culturing 
gonorrhoea diagnosed in high-risk groups to prevent transmission of drug-resistant strains.
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Introduction
This report describes current trends in the epidemiology of STIs, including HIV, in the 
Netherlands. It was prepared by the Centre for Infectious Disease Control (CIb) at the National 
Institute for Public Health and the Environment (RIVM). The CIb collaborates with various 
partners in the field of STI to collect data for surveillance and to generate insights into trends 
and determinants: the STI clinics, the Stichting HIV Monitoring (SHM), public health laborato-
ries, general practitioners participating in the NIVEL Primary Care Database and other health 
care providers.
The data systematically collected among high-risk groups by the nationwide network of STI 
clinics under the responsibility of the Public Health Services are the backbone of the Dutch STI 
surveillance on STI trends and risk factors. Other available STI data from surveys, screening 
programmes, national registries, cohort studies and other surveillance systems are included as 
much as possible. Together they provide an overview of the current status of STI, including 
HIV, in the Netherlands. Preliminary data have been presented in the Thermometer Seksuele 
Gezondheid (April 2014).
Outline of the report
Chapter 1 describes the methodology of each data source used for STI surveillance in the 
Netherlands. In Chapter 2, the characteristics of the STI clinic attendees and data from consul-
tations among young people (Sense) in 2013 are presented. Data from general practitioners for 
2012 are also presented, as well as trends in specific risk groups for 2004-2013. The Chapters 
3-5 present data on bacterial STI (chlamydia, gonorrhoea and syphilis) and the Chapters 6-10 
focus on viral STI, including HIV, genital warts, genital herpes and hepatitis B and C. 
Conclusions and recommendations are captured in Chapter 11.  
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1 
Methodology of STI and 
HIV surveillance
Tables and figures for this report are based on a variety of data sources in order to present an 
up-to-date overview of the STI/HIV epidemic in the Netherlands. The foundation of this 
overview is the systematic surveillance among high-risk groups embodied in the nationwide 
system of STI clinics. Data from general practitioners (GPs), who perform the bulk of STI 
consultations, are extrapolated from the NIVEL Primary Care Database. We used data from the 
anonymous HIV surveillance at STI clinics and the HIV treatment clinics (Stichting HIV 
Monitoring) to gain insight into trends among HIV patients in care. Other additional data 
sources were weekly virological laboratory reports, the Gonococcal Resistance to 
Antimicrobials Surveillance programme (GRAS), the antenatal screening and the data on 
hepatitis B and C notifications, the hepatitis B vaccination programme for risk groups and the 
blood donor registry.
1.1 National surveillance at STI clinics
Since 1995, STI diagnoses have been registered in an STI database at the RIVM in the 
Netherlands. In 2003, an STI sentinel surveillance system was put in place and this achieved 
national coverage with the inclusion of all STI clinics in 2004. Since 2006, reporting to the 
national STI surveillance system has been organized into eight regions. One of the STI clinics in 
each region is responsible for the coordination of STI surveillance (Figure 1.1). In total, 26 STI 
clinics, mostly within the Public Health Services (PHSs), provide low threshold STI/HIV testing 
and care, which is free of charge and targeted at high-risk groups. Persons matching one of the 
following criteria are considered to be at high-risk of STI acquisition: (1) reporting STI-related 
symptoms, (2) notified or referred for STI testing, (3) aged below 25 years, (4) men who have 
sex with men (MSM), (5) involved in commercial sex, (6) originating from an HIV/STI endemic 
area, (7) reporting three or more sexual partners in the previous six months or (8) reporting a 
partner from one of these risk groups. Attendees are mandatorily tested for chlamydia, 
gonorrhoea and syphilis and there is an opt-out policy for HIV testing. Since 2012, attendees 
below the age of 25 years with no other inclusion criteria are in principle tested for chlamydia 
only. If the chlamydia test result was positive, further testing for gonorrhoea, syphilis and HIV 
was offered. Hepatitis B and C, genital herpes, trichomonas and LGV are only tested on 
indication or diagnosed based on symptoms. 
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Figure 1.1: Eight regions with coordinating STI clinic indicated.
Regio Noord-Holland en Flevoland
GGD Amsterdam
Regio Noord
GGD Groningen
Regio Oost
GGD Nijmegen
Regio Utrecht
GG & GD Utrecht
Regio Limburg
GGD Zuid Limburg
Regio Zeeland Brabant
GGD Hart voor Brabant
Regio Noordelijk Zuid-Holland
GGD Den Haag, Dienst OCW
Regio Zuidelijk Zuid-Holland
GGD Ro erdam-Rijnmond
All consultations and corresponding diagnoses are reported online to the RIVM for surveillance 
purposes; a process that is facilitated by a web-based application (SOAP). The unit of analysis 
is ‘new STI consultation’ and anonymised reports contain epidemiological, behavioural, clinical 
and microbiological data on a wide range of STI.
In this report, the results of national surveillance of STI clinics are presented with respect to 
the number and nature of new consultations and diagnoses. Trends in positivity rates by risk 
profile (based on demographic and behavioural indicators) in time are based on data from the 
STI clinics under national surveillance from 2004 to 2013. Where data were not complete for a 
specific period or STI clinic, this is indicated. We focus on the major bacterial and viral STI, 
including HIV infection.
1.2 Sense
To strengthen primary prevention and to promote sexual health among young adults (< 25 
years), the STI clinics could also provide sexual health consultations (Sense consultations). 
Young adults can anonymously approach these Sense locations for information and personal 
consultations on a broad range of subjects relating to sexual health, including (problems with) 
sexual intercourse, unwanted pregnancy, birth control, STI, homosexuality, sexual violence or 
lover-boys. Data on the number and the demographics of visitors of the Sense consultations 
are presented. 
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1.3 STI surveillance in general practice
Prevalence rates of STI’s in general practice were calculated with data from routine electronic 
health record systems of general practices participating in NIVEL Primary Care Database 
(NIVEL-PCD), which incorporates the former LINH (Landelijk Informatie Netwerk 
Huisartsenzorg), maintained at the Netherlands Institute for Health Services Research (NIVEL). 
NIVEL-PCD uses routinely recorded data from health care providers to monitor health and 
utilisation of health services in a representative sample of the Dutch population. In 2012, there 
was a fourfold increase of the number of participating general practices in NIVEL-PCD compa-
red to the previous group of LINH practices, resulting in a representative sample of 386 
participating general practices with approximately 1.2 million registered patients (http://www.
nivel.nl/NZR/zorgregistraties-eerstelijn). Prevalence rates from NIVEL-PCD were calculated 
with an adjusted procedure: there were changes in definitions of episodes and in calculations 
of prevalence (i.e. more specific selection of patient years1), which caused an increase in nearly 
all STI numbers. Because of these changes, we decided to report previously published num-
bers of STI-episodes and STI prevalence rates based on the old method from 2002 to 2011 
from our previous annual reports.2 Additionally, we report numbers of STI-episodes and STI 
prevalence rates using the new method for 2010, 2011 and 2012.  
In NIVEL-PCD, all complaints and illnesses are recorded using International Classification of 
Primary Care (ICPC-1). Annual prevalence estimates of the total number of episodes seen at 
GPs in the Netherlands were made by extrapolation of the reporting rates in these practices to 
the total number of Dutch residents, as obtained from Statistics Netherlands (CBS), reported 
by gender. For chlamydia, which does not have a main ICPC code, we counted ICPC main codes 
with appropriate prescription registered in a separate database. Among women the main 
codes included were for cervicitis, vaginitis and Pelvic Inflammatory Disease (PID), among men 
for orchitis/epididymitis and other genital diseases (the latter general code only when the start 
of episode was in the year or last 2 months of the previous year).3 For syphilis, the number of 
cases reported was too small for reliable estimates.
We estimated the prevalence of patients with at least one episode per 100,000 patient-years. 
Episode-duration is defined by the time between the first and the last consultation registered 
with the same code, and an additional period where patients are considered not susceptible (8 
weeks for acute morbidities/complaints). We chose to include data from a selection of 74 
practices that consistently reported good quality data between 2010 to 2012. For HIV, we 
report prevalence estimations using NIVEL-PCD. HIV is defined as a ‘chronic, non-reversible 
morbidity’ in the new database, which remain prevalent as long as the patient is registered in 
the network. In previous annual reports, estimates for HIV were not reported because of the 
uncertainty due to the small number of practices and the inability to calculate prevalence for 
chronic illnesses. 
1   Nielen MMJ, Spronk I, Davids R, Zwaanswijk M, Verheij RA, Korevaar JC. Verantwoording incidentie en prevalentie cijfers van gezondheidsproblemen in de 
Nederlandse huisartsenpraktijk in 2012. Uit: NIVEL Zorgregistraties eerste lijn [https://www.nivel.nl/NZR/symptomen-en-aandoeningen]. 2013 [Laatst gewijzigd 
op 16-12-2013; geraadpleegd op 24-04-2014]. URL: www.nivel.nl/node/3619
2 Stirbu-Wagner I, Dorsman SA, Visscher S, et al. Landelijk Informatienetwerk Huisartsenzorg. Feiten en cijfers over huisartsenzorg in Nederland. Utrecht/
Nijmegen: NIVEL/IQ, 2010. <http://www.LINH.nl>, accessed 20-03-2013.
3  van den Broek IVF, Verheij RA, van Dijk CE, Koedijk FDH, van der Sande MAB, van Bergen JEAM. Trends in sexually transmitted infections in the Netherlands, 
combining surveillance data from general practices and sexually transmitted infection centers. BMC Family Practice, 2010, 11:39.
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Furthermore, more detailed data on STI consultations in general practice are reported from a 
subset of practices in NIVEL-PCD: the Dutch Sentinel General Practice Network (CMR peilstati-
ons). Since 2008, 40-45 general practices participating in additional reporting within this 
network complete a questionnaire for new consultations concerning STI/HIV issues. The 
questionnaire addresses STI testing, diagnoses and background information on the patient 
characteristics with reference to ethnicity, sexual preference and sexual behaviour.4 We report 
the main results on patients’ profile, testing rates and positivity as well as trends from 2008 to 
2012. 
1.4 Laboratory surveillance
National laboratory surveillance data are not available for STI, except for data from the 
‘Virologische Weekstaten’, which include the total number of Chlamydia trachomatis positive 
tests. Data from 21 laboratories, covering an estimated 40 per cent of the main laboratories in 
the Netherlands) were analysed.5 There is overlap between the laboratories reporting in this 
system and the laboratories connected to the STI clinics.
1.5 Antimicrobial resistance of gonococci
Concern for increasing resistance to quinolones at (inter)national level led to an RIVM labora-
tory survey of the resistance of gonococci in 2002. Because the results demonstrated the need 
for systematic nationwide surveillance of gonococcal antimicrobial resistance, the Gonococcal 
Resistance to Antimicrobials Surveillance programme (GRAS) was implemented in the 
Netherlands in 2006. This programme consists of the systematic collection of data on gonor-
rhoea and resistance patterns linked with epidemiological data.  The participating STI clinics 
were responsible for 84 per cent of all gonorrhoea diagnoses in 2013.
1.6 Congenital syphilis
For many years, the RIVM has offered Immunoglobulin M (IgM) diagnostics for neonates and 
young infants (< 1 year) who are suspected of being infected with congenital syphilis. In this 
report, results from 1997–2013 are presented. 
1.7 Antenatal screening
Each year, around 185,000 pregnant women are screened for syphilis (since the 1950s), 
hepatitis B virus (HBV) (1989) and HIV (2004) in the Netherlands. The blood sample is collected 
during the first midwife appointment (< 13th week of the pregnancy) according to the opting-
 4 Trienekens SC, van den Broek IV, Donker GA, van Bergen JE, van der Sande MA. Consultations for sexually transmitted infections in the general practice in the 
Netherlands: an opportunity to improve STI/HIV testing. BMJ Open. 2013 Dec 30;3(12):e003687. doi: 10.1136/bmjopen-2013-003687.
5 Virologische weekstaten,  http://www.rivm.nl/Onderwerpen/Onderwerpen/S/Surveillance_van_infectieziekten/Virologische_weekstaten , accessed 29-3-2014
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out principle. Pregnant women undergo the test, after being provided with information, unless 
they explicitly state that they do not wish to participate. Almost all pregnant women in the 
Netherlands participate in this infectious diseases screening programme.6 7  The screening 
programme is coordinated by the Centre for Population Screening (CvB). 
1.8 National registration of patients registered at HIV treatment   
 centres
From January 2002, an anonymous HIV/AIDS reporting system for patients entering care was 
implemented in the Netherlands. Longitudinal data of all newly registered HIV-infected 
individuals who give their consent are collected by the SHM (www.hiv-monitoring.nl). The goal 
of SHM is to monitor HIV-infected individuals registered at the 27 recognised HIV treatment 
centres (including four children’s centres) in the Netherlands in order to study changes in the 
epidemic, the natural history of HIV and the effects of treatment. 
All HIV-infected individuals registered in this cohort are followed prospectively from the time 
they entered HIV. HIV-infected individuals in care, who were diagnosed prior to the start of 
SHM, were included in the cohort retrospectively. HIV cases diagnosed before 1996 only 
include people who survived up to the start of the ATHENA clinical cohort in 1996. The epide-
miological data on newly reported HIV infections, as well as trends in new AIDS diagnoses 
after 2000, are reported in collaboration with the CIb at the RIVM.
Between 1987 and 2002, AIDS cases were reported on a voluntary basis to the Inspectorate of 
Health (national AIDS registry, IGZ). With the start of the SHM monitoring system in 2002 the 
national AIDS registry was ended. In this report, AIDS cases from 1999 or earlier are obtained 
from the AIDS registry. From 2000, AIDS cases from the SHM monitoring system were used. 
Data on deaths among HIV/AIDS patients were obtained from 2002 onwards through the SHM 
(before 2002 from National Statistics Netherlands (www.cbs.nl)). 
 
1.9 HIV incidence data
HIV incidence data are obtained from the Amsterdam Cohort Studies (ACS) on HIV/AIDS, which 
started in 1984 among MSM and in 1985 among injecting drug users (IDUs). From 1995 and 
1998, recruitment started among young (< 30 years) MSM and IDUs, respectively. Since April 
2006, participation has again been open to MSM of all ages with at least one sexual partner in 
the preceding six months. The ACS is a collaboration between the Public Health Service 
Amsterdam, the Academic Medical Centre Amsterdam, the Sanquin Blood Supply Foundation 
and the University Medical Centre Utrecht. The programme is financially supported by the 
RIVM (www.amsterdamcohortstudies.org).
6 Procesmonitoring prenatale screening infectieziekten en erythrocytenimmunisatie 2005–2007, TNO, Leiden, 2012.
7  ELM Op de Coul, JWM van Weert, PJ Oomen, et al. Prenatale screening op hiv, hepatitis B en syfilis in Nederland effectief. Ned Tijdsch Geneeskd 2010 4 
december; 154 (48): 2219-2225.
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1.10  Notification of hepatitis B and C
The obligatory notification includes epidemiological data on newly diagnosed acute HBV 
infections (since 1976), chronic HBV infections and acute hepatitis C virus (HCV) infections 
(both since April 1999). Since 2002, all Public Health Services have notified HBV and HCV 
infections by using the web-based application OSIRIS.
1.11 Hepatitis B vaccination programme for risk groups
As a low-endemic country, the Netherlands adopted a vaccination programme against HBV, 
targeted at groups with high-risk behaviour. The programme offers free vaccination to MSM 
and commercial sex workers. Heterosexuals with an indication for an STI were also considered 
a risk group until October 2007 and drug users until January 2012. PHSs and STI clinics offer 
free of charge vaccination according to the six-month schedule. Participants are tested 
serologically for markers of previous or current hepatitis B infection during their consultation 
for a first vaccination. Data were collected from the registration system especially developed 
for the vaccination programme. Although universal childhood vaccination was adopted in 
2011, the current targeted risk group vaccination programme will be continued in the coming 
years.
1.12 Blood donors
Since 1985 blood donated by (new and regular) blood donors has been screened for HIV, HBV, 
HCV, and syphilis, and positive blood is not used for blood transfusion. Volunteers are 
screened according to quality and safety guidelines and people who report specific risk factors 
for blood-transmitted infections are not accepted as donors. Records are kept in the national 
donor registry, which provides good information on the prevalence and incidence of these 
infections in a low-risk population. Data from 1998 onwards are reported. Incidences were 
calculated with the data provided by the blood bank register (www.sanquin.nl). 
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2 
STI and Sense consultations
2.1 Key points
STI clinics
• In 2013, 133,585 new consultations were registered by STI clinics under national surveillance, 
an increase of 10.1 per cent compared with 2012. The increase was highest among women 
(12.2 per cent). 
• Key characteristics of attendees were as follows: young age (48.7 per cent under 25 years); 
Dutch origin (66.6 per cent); female and heterosexual male (48.8 per cent and 30.6 per cent, 
respectively); 3 or more sexual partners in the previous 6 months (51.6 per cent), a history of 
STI in the previous 2 years (10.3 per cent) and not previously tested for HIV (39.5 per cent).
• Of the attendees who described the last sexual contact as casual, 64.7 per cent reported no 
condom use. 
• For the first time since 2007, the percentage of clients with at least one STI slightly declined: 
from 15.1 per cent in 2012 to 14.7 per cent in 2013. 
• The STI positivity rate in young people was, as always, higher among those aged 15-19 years 
than among those aged 20-24: 19.9 per cent versus 15.3 per cent respectively in 2013.
• Among MSM, the STI positivity rate was highest in those with a new HIV infection (51.4 per 
cent and in those with a known HIV positive status (31.5 per cent). While among known 
HIV-positive MSM the STI positivity rate has decreased over time, the STI positivity among 
MSM newly diagnosed with HIV has increased.
• Non-Dutch MSM tested more often positive for an STI (21.7 per cent) than Dutch MSM (18.2 
per cent).
• The percentage of STI clinic attendees who reported being notified of their possible expo-
sure to STI has increased from 10.8 per cent in 2010 to 15.0 per cent in 2013. In 2013, this 
percentage was highest among MSM (MSM: 18.5 per cent; heterosexual men: 17.9 per cent; 
women: 11.8 per cent).
• Among all individuals diagnosed with an STI, 31.4 per cent were detected through partner 
notification.
• In 2013, 11,029 Sense consultations were registered, of which 80.9 per cent were for women. 
Among both men and women, the most common topic was STI. Birth control was the 
second most common topic among women.
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General practice
• Using the new method, the annual number of STI-related episodes at GPs (based on ICPC 
codes for episodes of fear of STI and diagnoses of STI) was estimated at 340,000 in the 
Netherlands in 2012 and was stable compared to 2010 and 2011. Due to changes in defini-
tions, the estimated numbers for 2010-2012 were higher using the new method data than 
the numbers reported previously (see Chapter 2: Methodology). 
• Of all STI-related episodes at GPs in 2012, 47 per cent were in men and 53 per cent in women. 
In about 50 per cent of the STI-related consultations, a diagnosis of STI was registered 
(chlamydia, gonorrhoea, syphilis, HIV, trichomonas, genital herpes, genital warts or non-
specific urethritis).
• The more detailed data from questionnaires (Dutch Sentinel General Practice Network, 
NIVEL) also show that the patients with STI-related consultations at GPs were more often 
women (58 per cent) than men. The majority (80 per cent) is of Dutch descent and about 40 
per cent is under 25 years. Eight to 10 per cent of male STI-patients indicated having a 
homosexual preference, which is much lower than at  STI clinics, where 40 per cent of male 
clients reported being MSM. The most common reason to visit the GP for STI issues is STI 
symptoms or complaints (43 per cent). Since the start of reporting, these characteristics of 
patients with STI-related consultations at the GP have not changed over time.
• In 2012, GPs requested an STI-test (chlamydia, gonorrhoea, syphilis or HBV) in 80 per cent of 
STI-consultations, and an HIV-test in 24 per cent. The HIV-test request rate declined slightly 
between 2008 and 2012 for heterosexual men and women, while this was stable for MSM. 
The STI test positivity rate (chlamydia, gonorrhoea, syphilis, HBV, HIV) was 30 per cent, but it 
was higher among patients under 25 years (38 per cent) and patients who were notified (54 
per cent). 
27Sexually transmitted infections, including HIV, in the Netherlands in 2013
Figure 2.1 Positivity rates of STI by region, the Netherlands, 2013.
Positivity rate
12 - 14%
14 - 16%
16 - 18%
Footnote: STI include: chlamydia, gonorrhoea, infectious syphilis, HIV and infectious hepatitis B.
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2.2 Consultations and characteristics of STI clinic attendees
Footnote: 1995–2002: STI registration; 2000: STI clinic Erasmus Medical Centre Rotterdam was included; 
2003: Implementation of STI sentinel surveillance network; 2004–2013: National STI surveillance 
network. STI include: chlamydia, gonorrhoea, infectious syphilis, HIV and infectious hepatitis B.
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Figure 2.2 Number of consultations and percentage of positive STI in the national STI 
surveillance in the Netherlands, 1995–2013.
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Gender and sexual 2008 2009 2010 2011 2012 2013
preference n (%) n (%) n (%) n (%) n (%) n (%)
Heterosexual men 31,770 
(35.9)
32,584 
(34.9)
35,112 
(33.4)
37,434 
(33.1)
38,516 
(31.8)
40,872 
(30.6)
MSM 13,764 
(15.6)
16,332 
(17.5)
19,579 
(18.6)
21,783 
(19.2)
24,640 
(20.3)
27,497 
(20.6)
Women 42,796 
(48.4)
44,291 
(47.5)
50,177 
(47.8)
53,849 
(47.6)
58,040 
(47.9)
65,104 
(48.7)
Transgender* 34 
(0.04)
47 
(0.1)
76 
(0.1)
46 
(0.04)
42 
(0.03)
54 
(0.0)
Sexual preference 
unknown*
71 
(0.1)
77 
(0.1)
72 
(0.1)
68 
(0.1)
40 
(0.03)
58 
(0.0)
Total 88,435 93,331 105,016 113,180 121,278 133,585
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nr of consultations
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% positive STI
MSM: nr of consultations MSM: % positive STI
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Table 2.1 Number of consultations by sexual risk group, 2007–2013.
*The categories ‘transgender’ and ‘sexual preference unknown’ are excluded from here onwards.
Figure 2.3 Number of consultations and percentage of positive STI tests in the national STI 
surveillance in the Netherlands by gender and sexual preference, 2004–2013.
Footnote: STI include: chlamydia, gonorrhoea, infectious syphilis, HIV and infectious hepatitis B. 
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Footnote: STI include: chlamydia, gonorrhoea, infectious syphilis, HIV and infectious hepatitis B.
Age (years) Heterosexual 
men
MSM Women Total
 n (%) n (%) n (%) n (%)
≤14 8 (0.0) 2 (0.0) 83 (0.1) 93 (0.1)
15–19 2,567 (6.3) 738 (2.7) 8,559 (13.1) 11,864 (8.9)
20–24 16,615 (40.7) 3,831 (13.9) 32,643 (50.1) 53,089 (39.8)
25–29 9,388 (23.0) 4,023 (14.6) 11,699 (18.0) 25,110 (18.8)
30–34 4,185 (10.2) 3,518 (12.8) 4,174 (6.4) 11,877 (8.9)
35–39 2,291 (5.6) 3,336 (12.1) 2,309 (3.5) 7,936 (5.9)
40–44 1,974 (4.8) 3,414 (12.4) 2,149 (3.3) 7,537 (5.6)
45–49 1,565 (3.8) 3,284 (11.9) 1,823 (2.8) 6,672 (5.0)
50–54 1,117 (2.7) 2,412 (8.8) 1,030 (1.6) 4,559 (3.4)
≥ 55 1,157 (2.8) 2,937 (10.7) 626 (1.0) 4,720 (3.5)
Unknown 5 (0.0) 2 (0.0) 9 (0.0) 16 (0.01)
Total 40,872 27,497 65,104 133,473
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Table 2.2 Number of consultations by age, gender and sexual preference, 2013.
Figure 2.4 Percentage of positive STI tests in the national STI surveillance in the Netherlands 
by age and sexual preference, 2013.
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Table 2.3 Number of consultations by ethnicity, gender and sexual preference, 2013.
Ethnicity Heterosexual 
men
MSM Women Total
 n (%) n (%) n (%) n (%)
The Netherlands 25,100 (61.4) 19,443 (70.7) 44,286 (68.0) 88,829 (66.6)
Turkey 1,078 (2.6) 347 (1.3) 620 (1.0) 2,045 (1.5)
First generation migrants 310 (28.8) 146 (42.1) 117 (18.9) 573 (28.0)
Second generation migrants 760 (70.5) 200 (57.6) 501 (80.8) 1,461 (71.4)
Unknown 8 (0.7) 1 (0.3) 2 (0.3) 11 (0.5)
North Africa/Morocco 1,748 (4.3) 348 (1.3) 1,124 (1.7) 3,220 (2.4)
First generation migrants 511 (29.2) 162 (46.6) 205 (18.2) 878 (27.3)
Second generation migrants 1,229 (70.3) 181 (52.0) 916 (81.5) 2,326 (72.2)
Unknown 8 (0.5) 5 (1.4) 3 (0.3) 16 (0.5)
Surinam 3,273 (8.0) 803 (2.9) 3,671 (5.6) 7,747 (5.8)
First generation migrants 1,048 (32.0) 349 (43.5) 945 (25.7) 2,342 (30.2)
Second generation migrants 2,200 (67.2) 437 (54.4) 2,709 (73.8) 5,346 (69.0)
Unknown 25 (0.8) 17 (2.1) 17 (0.5) 59 (0.8)
Netherlands Antilles/Aruba 1,706 (4.2) 553 (2.0) 1,660 (2.5) 3,919 (2.9)
First generation migrants 1,016 (59.6) 429 (77.6) 812 (48.9) 2,257 (57.6)
Second generation migrants 682 (40.0) 122 (22.1) 840 (50.6) 1,644 (41.9)
Unknown 8 (0.5) 2 (0.4) 8 (0.5) 18 (0.5)
Sub-Saharan Africa 1,418 (3.5) 228 (0.8) 1,491 (2.3) 3,137 (2.4)
First generation migrants 797 (56.2) 150 (65.8) 759 (50.9) 1,706 (54.4)
Second generation migrants 614 (43.3) 74 (32.5) 727 (48.8) 1,415 (45.1)
Unknown 7 (0.5) 4 (1.8) 5 (0.3) 16 (0.5)
Eastern Europe 600 (1.5) 567 (2.1) 2,734 (4.2) 3,901 (2.9)
First generation migrants 489 (81.5) 495 (87.3) 2,518 (92.1) 3,502 (89.8)
Second generation migrants 109 (18.2) 65 (11.5) 203 (7.4) 377 (9.7)
Unknown 2 (0.3) 7 (1.2) 13 (0.5) 22 (0.6)
Latin America 646 (1.6) 810 (2.9) 1,578 (2.4) 3,034 (2.3)
First generation migrants 443 (68.6) 699 (86.3) 1,186 (75.2) 2,328 (76.7)
Second generation migrants 196 (30.3) 90 (11.1) 383 (24.3) 669 (22.1)
Unknown 7 (1.1) 21 (2.6) 9 (0.6) 37 (1.2)
Asia 2,020 (4.9) 1,415 (5.1) 2,858 (4.4) 6,293 (4.7)
First generation migrants 983 (48.7) 736 (52.0) 1,116 (39.0) 2,835 (45.1)
Second generation migrants 1,032 (51.1) 674 (47.6) 1,729 (60.5) 3,435 (54.6)
Unknown 5 (0.2) 5 (0.4) 13 (0.5) 23 (0.4)
Europe other 2,144 (5.2) 2,083 (7.6) 3,244 (5.0) 7,471 (5.6)
First generation migrants 1,240 (57.8) 1,619 (77.7) 1,701 (52.4) 4,560 (61.0)
Second generation migrants 898 (41.9) 454 (21.8) 1,538 (47.4) 2,890 (38.7)
Unknown 6 (0.3) 10 (0.5) 5 (0.2) 21 (0.3)
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Table 2.3 (continued) Number of consultations by ethnicity, gender and sexual preference, 2013.
Ethnicity Heterosexual 
men
MSM Women Total
 n (%) n (%) n (%) n (%)
Else 303 (0.7) 328 (1.2) 516 (0.8) 1,147 (0.9)
First generation migrants 169 (55.8) 272 (82.9) 221 (42.8) 662 (57.7)
Second generation migrants 134 (44.2) 54 (16.5) 293 (56.8) 481 (41.9)
Unknown 0 (0.0) 2 (0.6) 2 (0.4) 4 (0.3)
Unknown 836 (2.0) 572 (2.1) 1,322 (2.0) 2,730 (2.0)
Total 40,872 27,497 65,104 133,473
Figure 2.5 Percentage of positive STI tests in the national STI surveillance in the Netherlands 
by ethnicity and sexual preference, 2013.
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Table 2.4 Number of consultations by (sexual) behavioural characteristics, gender and sexual 
preference, 2013.
Heterosexual 
men
MSM Women Total
n (%) n (%) n (%) n (%)
Number of partners in past 6 months 
0 partners 301 (0.7) 182 (0.7) 550 (0.8) 1,033 (0.8)
1 partner 8,075 (19.8) 2,833 (10.3) 19,487 (29.9) 30,395 (22.8)
2 partners 8,838 (21.6) 3,130 (11.4) 16,547 (25.4) 28,515 (21.4)
3 or more partners 23,178 (56.7) 20,397 (74.2) 25,262 (38.8) 68,837 (51.6)
Unknown 480 (1.2) 955 (3.5) 3,258 (5.0) 4,693 (3.5)
Condom use if last sexual contact was steady*
No 15,214 (78.4) 7,991 (76.7) 27,510 (83.7) 50,715 (80.9)
Yes 4,136 (21.3) 2,295 (22.0) 5,248 (16.0) 11,679 (18.6)
Unknown 66 (0.3) 131 (1.3) 105 (0.3) 302 (0.5)
Condom use if last sexual contact was casual*
No 14,008 (67.7) 8,920 (57.5) 19,977 (66.4) 42,905 (64.7)
Yes 6,582 (31.8) 6,439 (41.5) 9,961 (33.1) 22,982 (34.7)
Unknown 110 (0.5) 145 (0.9) 153 (0.5) 408 (0.6)
Previous GO/CT/syphilis in anamnesis
No 33,975 (83.1) 22,424 (81.6) 53,397 (82.0) 109,796 (82.3)
Yes 3,114 (7.6) 4,178 (15.2) 6,419 (9.9) 13,711 (10.3)
Don’t know 2,370 (5.8) 476 (1.7) 3,221 (4.9) 6,067 (4.5)
Unknown 1,413 (3.5) 419 (1.5) 2,067 (3.2) 3,899 (2.9)
Previous HIV test
No 20,268 (49.6) 3,402 (12.4) 29,014 (44.6) 52,684 (39.5)
Yes, positive 58 (0.1) 4,110 (14.9) 95 (0.15) 4,263 (3.2)
Yes, negative 19,764 (48.4) 19,779 (71.9) 34,577 (53.1) 74,120 (55.5)
Yes, result unknown 75 (0.2) 66 (0.2) 140 (0.2) 281 (0.2)
Unknown 707 (1.7) 140 (0.5) 1,278 (2.0) 2,125 (1.6)
CSW
No 40,677 (99.5) 26,975 (98.1) 59,258 (91.0) 126,910 (95.1)
Yes, in past 6 months 149 (0.4) 450 (1.6) 5,781 (8.9) 6,380 (4.8)
Unknown 46 (0.1) 72 (0.3) 65 (0.1) 183 (0.1)
Client of CSW, men
No 36,128 (88.4) 26,363 (95.9) 62,491 (91.4)
Yes, in past 6 months  4,638 (11.3) 678 (2.5) 5,316 (7.8)
Unknown 106 (0.3) 456 (1.7) 562 (0.8)
Swinger**
No 23,017 (92.9) 11,382 (90.0) 34,399 (91.9) 68,798 (91.9)
Yes 1,742 (7.0) 1,210 (9.6) 2,857 (7.6) 5,809 (7.8)
Unknown 14 (0.1) 56 (0.4) 185 (0.5) 255 (0.3)
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Table 2.4 (continued) Number of consultations by (sexual) behavioural characteristics, gender 
and sexual preference, 2013.
Heterosexual 
men
MSM Women Total
n (%) n (%) n (%) n (%)
Injecting drug use
No 40,212 (98.4) 27,175 (98.8) 63,284 (97.2) 130,671 (97.9)
Yes, ever 94 (0.2) 112 (0.4) 102 (0.2) 308 (0.2)
Yes, in past 6 months  28 (0.1) 77 (0.3) 35 (0.1) 140 (0.1)
Unknown 538 (1.3) 133 (0.5) 1,683 (2.6) 2,354 (1.8)
Social economic status (SES)
Very high 5,008 (12.3) 4,077 (14.8) 8,390 (12.9) 17,475 (13.1)
High 10,522 (25.7) 7,470 (27.2) 17,150 (26.34) 35,142 (26.3)
Medium 11,484 (28.1) 7,358 (26.8) 18,664 (28.7) 37,506 (28.1)
Low 6,771 (16.6) 4,587 (16.7) 9,952 (15.3) 21,310 (16.0)
Very low 4,204 (10.3) 2,131 (7.7) 5,472 (8.4) 11,807 (8.8)
Unknown 2,883 (7.1) 1,874 (6.8) 5,476 (8.4) 10,233 (7.7)
* Type of sexual contact was missing for 3 per cent (n=3,510)
** Voluntary question, answered by 53 per cent (n=70,977)
Table 2.5 Reported indication by gender and sexual preference, 2013.
Indication Heterosexual 
men
MSM Women Total
n (%) n (%) n (%) n (%)
STI/HIV endemic area 12,489 (30.6) 5,071 (18.4) 15,736 (24.2) 33,296 (24.9)
Symptoms 13,379 (32.7) 6,404 (23.3) 21,547 (33.1) 41,330 (31.0)
Partner in risk group 11,998 (29.4) 25,910 (94.2) 19,767 (30.4) 57,675 (43.2)
Notified 7,302 (17.9) 5,075 (18.5) 7,708 (11.8) 20,085 (15.0)
No indication 707 (1.7) 0 (0.0) 1,125 (1.7) 1,832 (1.4)
Footnote: Percentages do not add up to 100% since one client can have more than one indication.
Footnote: Other indications not shown in the table are: aged 24 years or younger, 3 or more partners in 
previous 6 months, MSM, CSW, client of CSW (men).
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Figure 2.6 Percentage of positive STI tests in the national STI surveillance in the Netherlands 
by risk factor and sexual preference, 2013
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Table 2.6a Number of STI diagnoses and percentage of positive tests by gender and sexual 
preference, 2013.
Diagnosis Heterosexual 
men
MSM Women Total
  n (% pos.) n (% pos.) n (% pos.) n (% pos.)
Chlamydia 5,201 (12.8) 2,645 (9.6) 7,921 (12.2) 15,767 (11.8)
Gonorrhoea 621 (1.6) 2,541 (9.3) 991 (1.8) 4,153 (3.4)
Syphilis, infectious* 31 (0.1) 581 (2.1) 14 (0.03) 626 (0.5)
HIV 15 (0.0) 315 (1.4) 26 (0.0) 356 (0.3)
Hepatitis B, infectious 77 (0.4) 48 (0.5) 47 (0.2) 172 (0.3)
Genital warts 883 (2.2) 463 (1.7) 711 (1.1) 2,057 (1.5)
*Infectious syphilis includes primary, secondary infection and latens recens
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Table 2.6b Number of STI diagnoses by gender and sexual preference, 2013.
Diagnosis Heterosexual 
men 
MSM Women Total
  n n n n
Syphilis
primary 14 189 5 208
secondary 6 146 1 153
latens recens 11 246 8 265
latens tarda 26 86 22 134
not specified 9 55 13 77
Genital herpes
primary: HSV1 81 35 143 259
primary: HSV2 105 62 129 296
primary: HSV 
unknown
11 7 33 51
recurrent 13 7 16 36
Hepatitis B, recovered 474 615 528 1,617
Hepatitis C 1 34 1 36
Non specified urethritis 799 465 4 1,268
Candidiasis 161 50 634 845
Bacterial vaginosis 3 1 1,290 1,294
Trichomoniasis 9 0 165 174
Scabies 17 15 7 39
Pubic Lice 0 7 0 7
Ulcus e.c.i. 4 3 5 12
Lymphogranuloma 
venereum 
0 106 0 106
Proctitis 0 184 3 187
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2.3 Trends
2.3.1 Trends in specific risk groups
Figure 2.7 Number of consultations and percentage of positive STI tests in the national STI 
surveillance in the Netherlands among MSM by ethnicity, 2004-2013.
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Footnote: Until 2010, ethnicity was self-reported. Since 1 January 2011, ethnicity has been based on the 
country of birth of the client and client’s parents; the 2011-2013 data can therefore not be directly 
compared with previous years
Figure 2.8 Number of consultations and percentage of positive STI tests in the national STI 
surveillance in the Netherlands among MSM by HIV status, 2004–2013.
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Figure 2.9 Number of consultations and percentage of positive STI tests in the national STI 
surveillance in the Netherlands among commercial sex workers, 2004–2013.
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Figure 2.10 Number of consultations and percentage of positive STI tests in the national STI 
surveillance in the Netherlands among young age groups, 2004–2013.
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Figure 2.11 Percentage of positive STI tests in the national STI surveillance in the Netherlands 
by ethnicity, 2004–2013.
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Footnote: Until 2010, ethnicity was self-reported. Since 1 January 2011, ethnicity has been based on the 
country of birth of the client and client’s parents; the 2011-2013 data can therefore not be directly 
compared with previous years.
Figure 2.12 Number and percentage of heterosexual men, MSM and women who reported 
having had an HIV test previously (including known HIV-positive individuals), 2007-2013.
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2.3.2 Partner notification trends
Figure 2.13 The number and the percentage of heterosexual men, MSM and women who 
reported being notified of their potential risk of exposure to STI, 2010-2013.
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Figure 2.14 The percentage of STI detected through partner notification among heterosexual 
men, MSM and women, and the percentage of HIV detected through partner notification 
among MSM, 2010-2013.
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2.4 General practitioner
Figure 2.15 PEstimated prevalence of episodes of fear of STI/HIV and the prevalence of STI 
positive episodes at GPs, based on extrapolation from general practices in the surveillance 
network of NIVEL-PCD, using the old method (2002-2011) and the new method (2010-2012).
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Footnote: Diagnoses included are chlamydia, gonorrhoea, syphilis, HIV, trichomonas, genital herpes, 
genital warts, non-specific urethritis. 
(Source: NIVEL Primary Care Database)
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Table 2.7 Estimated prevalence of STI-related episodes of diagnoses and fear of STI/HIV per 
100,000 population at GPs in the Netherlands by gender, based on extrapolation from the 
practices in the surveillance network of NIVEL-PCD, using the old method (2002-2011) and the 
new method (2010-2012).
 Men Women Total
  n/100,000 n/100,000 n/100,000
Old method 2002 605 727 615
2003 587 760 674
2004 748 937 843
2005 845 900 873
2006 828 992 910
2007 826 948 887
2008 1,216 1,309 1,262
2009 1,107 1,205 1,156
2010 1,043 1,115 1,079
2011 1,157 1,292 1,224
New method 2010 1,949 2,136 1,916
2011 1,812 1,943 1,744
2012 1,938 2,121 1,887
Footnote: Diagnoses included are chlamydia, gonorrhoea, syphilis, HIV, trichomonas, genital herpes, 
genital warts, non-specific urethritis. 
(Source: NIVEL Primary Care Database)
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Table 2.8 Characteristics of STI-patients seen in primary care surveillance (based on STI-
consultation questionnaires in 40-45 practices of the Dutch Sentinel General Practice Network, 
NIVEL), from 2008-2012.
   2008 2009 2010 2011 2012
N (%) N (%) N (%) N (%) N (%)
 Total 437 546 530 595 559
Gender and sexual 
preference
     
Women 259 (59.3) 310 (56.8) 315 (59.4) 356 (59.8) 318 (56.9)
Heterosexual men 152 (34.8) 202 (37.0) 185 (34.9) 195 (32.8) 179 (32.0)
MSM 18 (4.1) 22 (4.0) 16 (3.0) 23 (3.9) 28 (5.0)
Men unknown preference 10 (2.3) 11 (2.0) 14 (2.6) 18 (3.0) 20 (3.6)
Ethnic background
Dutch 360 (82.4) 446 (81.7) 460 (86.8) 497 (83.5) 437 (78.2)
non-Dutch non-Western 63 (14.4) 91 (16.7) 58 (10.9) 92 (15.5) 93 (16.6)
non-Dutch Western 7 (1.6) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
unknown 9 (2.1) 9 (1.6) 13 (2.5) 6 (1.0) 15 (2.7)
Age group
< 25 years 175 (40.0) 212 (38.8) 220 (41.5) 245 (41.2) 186 (33.3)
 > 25 years 262 (60.0) 334 (61.2) 310 (58.5) 350 (58.8) 373 (66.7)
Recent sexual contacts*
Steady partner 234 (53.5) 278 (50.9) 260 (49.1) 283 (47.6) 279 (49.9)
Casual partner(s) 171 (39.1) 209 (38.3) 199 (37.5) 233 (39.2) 214 (38.3)
Paid sex contacts 5 (1.1) 8 (1.5) 8 (1.5) 5 (0.8) 5 (0.9)
unknown 37 (8.5) 71 (13.0) 78 (14.7) 74 (12.4) 78 (14.0)
Reason for STI-
consultation
STI-related complaints 179 (41.0) 255 (46.7) 230 (43.4) 244 (41.0) 246 (44.0)
Notified 46 (10.5) 48 (8.8) 60 (11.3) 73 (12.3) 75 (13.4)
Check-up 75 (17.2) 118 (21.6) 98 (18.5) 104 (17.5) 86 (15.4)
Recent risk 62 (14.2) 73 (13.4) 69 (13.0) 98 (16.5) 76 (13.6)
Fear for STI 27 (6.2) 39 (7.1) 24 (4.5) 17 (2.9) 16 (2.9)
other/unknown 48 (11.0) 13 (2.4) 49 (9.2) 59 (9.9) 60 (10.7)
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Table 2.9 Testing rate and positivity rate for STI (chlamydia, gonorrhoea, syphilis, HepB) and 
HIV and positivity rate among persons tested (Dutch Sentinel General Practice Network, 
NIVEL), 2012.
STI test HIV test#
N tests % tested   N pos % pos N tests  % tested
Gender and sexual 
preference
      
Women 246 77.4 66 26.8 66 20.8
Heterosexual men 138 77.1 39 28.3 48 26.8
MSM 25 89.3 8 32.0 11 39.3
Ethnic background      
Dutch 343 78.5 91 26.5         105 24.0
non-Dutch non-Western 76 81.7 25 32.9           22 23.7
Age group      
< 25 years 153 82.3 58 37.9           43 23.1
> 25 years 279 74.8 64 22.9           89 23.9
Recent sexual contacts*      
Steady partner 206 73.8 63 30.6           62 22.2
Casual partner(s) 185 86.4 45 24.3           59 27.6
Paid sex contacts 5 100.0 2 40.0            1 20.0
unknown 54 69.2 20 37.0           18 23.1
Reason for STI-
consultation
  
STI-related complaints 167 67.9 58 34.7           27 11.0
Notified 61 81.3 33 54.1           14 18.7
Check-up 80 93.0 16 20.0           43 50.0
Recent risk 73 96.1 12 16.4           29 38.2
Fear for STI 10 62.5 0 0.0            4 25.0
other/unknown 50 83.3 12 24.0           20 33.3
*  Some patients are included in more than one category
#  All HIV tests were negative
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Figure 2.16 Testing rate for STI (chlamydia, gonorrhoea, syphilis, HepB) and HIV in the Dutch 
Sentinel General Practice Network, NIVEL, 2008-2012.
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2.5 Sense
Table 2.10 Number of Sense consultations by age and gender, 2013.
Age (years) Men Women Total
 n (%) n (%) n (%)
≤ 14 18 (0.8) 160 (1.7) 178 (1.5)
15–19 598 (26.7) 3,221 (34.0) 3,819 (32.6)
20–24 1,377 (61.5) 5,596 (59.1) 6,973 (59.5)
≥ 25 247 (11.0) 496 (5.2) 743 (6.3)
Total 2,240 9,473 11,713
Footnote: Six transgenders were excluded from the analyses. Age was missing for six consultations.
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Figure 2.17 Number of Sense consultations by gender, 2010–2013.
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Footnote: Six transgenders were excluded from the analyses. 
Table 2.11 Number of Sense consultations by country of birth and gender, 2013.
Country of birth Men Women Total
 n (%) n (%) n (%)
The Netherlands 1,518 (67.7) 6,724 (70.9) 8,242 (70.3)
Netherlands Antilles 112 (5.0) 252 (2.7) 364 (3.1)
Surinam 100 (4.5) 340 (3.6) 440 (3.8)
Morocco 68 (3.0) 183 (1.9) 251 (2.1)
Turkey 48 (2.1) 135 (1.4) 183 (1.6)
Else 395 (17.6) 1,844 (19.5) 2,239 (19.1)
Total 2,241 9,478 11,719
Footnote: Six transgenders were excluded from the analyses. 
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Table 2.12 Subjects of Sense consultations by gender, 2013.
Men Women
Subjects n (%) n (%)
STI 1,044 (46.5) 1,915 (20.1)
Sexuality 751 (33.5) 1,598 (16.8)
Birth control 46 (2.0) 3,080 (32.3)
Unwanted sexual behaviour/sexual violence 32 (1.4) 374 (3.9)
Unintended pregnancy 9 (0.4) 827 (8.7)
Fertility 2 (0.1) 15 (0.2)
Else 206 (9.2) 678 (7.1)
Unknown 154 (6.9) 1,039 (10.9)
Total 2,244 9,526
Footnote: Six transgenders were excluded from the analyses. 
Footnote: Numbers do not add up to the total number of consultations, due to a different format of 
registration. For 690 consultations, 741 subjects of sense consultations were registered and STI was no 
longer reported as a subject. 
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3 
Chlamydia, including 
lymphogranuloma 
venereum
3.1 Key points
• Chlamydia is the most commonly diagnosed bacterial STI: 15,767 cases were diagnosed at 
STI clinics in 2013 (50.2 per cent women, 33.0 per cent heterosexual men and 16.8 per cent 
MSM). 
• The overall positivity rate slightly decreased, from 12.2 per cent  in 2012 to 11.8 per cent in 
2013, due to decreased rates in MSM (10.4 to 9.6 per cent) and in heterosexual men (13.3 to 
12.8 per cent) but not in women (12.2 per cent in both years). 
• Of all chlamydia positive cases in 2013, 60.8 per cent were under 25 years of age. The highest 
positivity rates were observed in heterosexual women and men aged 15–19 years (19.7 and 
17.1 per cent, respectively). 
• The majority of the cases were found among native Dutch STI-clinic attendees, which also 
comprised the largest group tested. The highest overall positivity rate was found in people 
of Surinamese or Dutch Antillean descent (15.3 and 17.8 per cent respectively). 
• Other groups at high risk of chlamydia were people who reported a previous STI (gonor-
rhoea, chlamydia and/or syphilis; 16.2 per cent) and known HIV-positive MSM (15.9 per cent). 
• In 2013, 16,301 young people aged under 25 with no other risk factors were tested for 
chlamydia only; 1,273 of them tested positive (7.8 per cent) and were therefore retested for 
other STIs as well. Among these, 14 cases of gonorrhoea (1.1 per cent) and no cases of 
syphilis or HIV were reported. 
• Between 2010 and 2012, an estimated 46,000 cases of chlamydia were diagnosed at GPs 
annually using NIVEL-PCD data. In 2012, the estimated number of chlamydia episodes was 
273 per 100,000 population. The number of cases was higher using the new method than the 
previously reported numbers using the old method, probably due to changes in definitions 
(see Chapter 2: Methodology).
• The number of LGV cases in 2013 was 106, a strong decrease after the steep rise seen in 2012 
(184 cases in 2012). The positivity rate decreased as well, from 12.7 per cent in 2012 to 6.7 per 
cent in 2013. The profile of LGV cases was similar to that of previous years: 78 per cent were 
known HIV-positive; in two patients, a new HIV infection was diagnosed (1.9 per cent).
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Figure 3.1 Positivity rates of chlamydia by region, the Netherlands, 2013.
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3.2 STI clinics: characteristics, risk groups and trends
Table 3.1 Number of positive tests and persons tested for chlamydia by age, gender and sexual 
preference, 2013.
Age 
(years)
Heterosexual men MSM Women
n positive N tested n positive N tested n positive N tested
≤14 0 8 0 2 10 83
15–19 439 2,561 68 735 1,683 8,554
20–24 2,608 16,584 382 3,817 4,391 32,607
25–29 1,266 9,359 414 4,009 1,124 11,681
30–34 442 4,166 365 3,512 293 4,166
35–39 152 2,275 309 3,327 147 2,305
40–44 116 1,964 308 3,405 96 2,145
45–49 74 1,555 343 3,281 91 1,816
50–54 55 1,112 223 2,406 52 1,029
≥ 55 48 1,152 233 2,933 34 624
Unknown 1 5 0 2 0 9
Total 5,201 40,741 2,645 27,429 7,921 65,019
Figure 3.2 Percentage of positive tests of chlamydia by age, gender and sexual preference, 2013.
0 
5 
10 
15 
20 
25 
%
 p
os
iti
ve
 
15–19 20–24 25–29 30–34 35–39 40–44 45–49 50–54  ≥55 
heterosexual men
age (years)
MSM women
54 Sexually transmitted infections, including HIV, in the Netherlands in 2013
Table 3.2 Number of positive tests and persons tested for chlamydia by ethnicity, gender and 
sexual preference, 2013.
Ethnicity Heterosexual men MSM Women
n positive N tested n positive N tested n positive N tested
The Netherlands 2,957 25,019 1,813 19,395 5,395 44,230
Turkey 112 1,073 45 346 99 619
North Africa/
Morocco
215 1,740 38 348 166 1,123
Surinam 572 3,266 93 801 520 3,665
Netherlands 
Antilles/Aruba
340 1,704 67 551 288 1,660
Sub-Saharan 
Africa
268 1,415 16 227 181 1,489
Eastern Europe 66 596 57 567 240 2,731
Latin America 107 643 92 809 153 1,573
Europe other 243 2,137 183 2,081 361 3,239
Asia 216 2,012 153 1,408 344 2,856
Else 29 303 34 326 71 515
Unknown 76 833 54 570 103 1,319
Natives 2,957 25,019 1,813 19,395 5,395 44,230
First generation 
migrants
929 6,981 534 5,046 973 9,564
Second generation 
migrants
1,232 7,835 239 2,344 1,443 9,829
Unknown 83 906 59 644 110 1,396
Total 5,201 40,741 2,645 27,429 7,921 65,019
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Figure 3.3 Percentage of positive tests for chlamydia by ethnicity, gender and sexual 
preference, STI clinics, the Netherlands, 2013.
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Table 3.3 Number of positive tests and persons tested for chlamydia by sexual behavioural 
characteristics, gender and sexual preference, 2013.
  Heterosexual men MSM Women
 n positive/N % n positive/ N % n positive/N %
Number of partners in past 6 months 
0 partners 15/296 5.1 6/178 3.4 31/545 5.7
1 partner 1,001/8,023 12.5 173/2,817 6.1 2,474/19,449 12.7
2 partners 1,123/8,808 12.7 251/3,125 8.0 2,174/16,535 13.1
3 or more partners 3,021/23,138 13.1 2,101/20,366 10.3 3,023/25,237 12.0
Unknown 41/476 8.6 114/943 12.1 219/3,253 6.7
Condom use if last sexual contact was casual*
No 1,994/13,972 14.3 1,027/8,907 11.5 2,496/19,960 12.5
Yes 646/6,566 9.8 573/6,431 8.9 829/9,944 8.3
Unknown 12/109 11.0 10/144 6.9 10/153 6.5
Condom use if last sexual contact was steady* 
No 2,111/15,157 13.9 759/7,979 9.5 3,856/27,470 14.0
Yes 378/4,121 9.2 184/2,291 8.0 578/5,241 11.0
Unknown 9/66 13.6 8/131 6.1 14/105 13.3
Previous GO/CT/syphilis in anamnesis 
No 4,176/33,856 12.3 2,010/22,375 9.0 6,197/53,321 11.6
Yes 556/3,109 17.9 573/4,164 13.8 1,088/6,415 17.0
Don’t know 311/2,364 13.2 31/475 6.5 413/3,219 12.8
Unknown 158/1,412 11.2 31/415 7.5 223/2,064 10.8
Previous HIV test 
No 2,823/20,213 14.0 304/3,394 9.0 4,056/28,977 14.0
Yes, positive 9/58 15.5 651/4,100 15.9 13/95 13.7
Yes, negative 2,274/19,693 11.5 1,662/19,736 8.4 3,675/34,533 10.6
Yes, result unknown 11/75 14.7 10/66 15.2 20/140 14.3
Unknown 84/702 12.0 18/133 13.5 157/1,274 12.3
CSW
No 5,182/40,550 12.8 2,582/26,909 9.6 7,540/59,179 12.7
Yes, in past 6 
months
15/146 10.3 55/449 12.2 374/5,776 6.5
Unknown 4/45 8.9 8/71 11.3 7/64 10.9
Client of CSW, men 
No 4,867/36,026 13.5 2,585/26,297 9.8
Yes, in past 6 
months
324/4,610 7.0 38/677 5.6
Unknown 10/105 9.5 22/455 4.8   
Swinger**
No 3,136/22,940 13.7 1,167/11,349 10.3 4,607/34,355 13.4
Yes 75/1,742 4.3 70/1,210 5.8 166/2,855 5.8
Unknown 3/14 21.4 4/56 7.1 9/185 4.9
57Sexually transmitted infections, including HIV, in the Netherlands in 2013
Table 3.3 (continued) Number of positive tests and persons tested for chlamydia by sexual 
behavioural characteristics, gender and sexual preference, 2013.
  Heterosexual men MSM Women
 n positive/N % n positive/ N % n positive/N %
SES 
Very high 559/4,999 11.2 362/4,071 8.9 1,006/8,378 12.0
High 1,287/10,493 12.3 722/7,460 9.7 2,027/17,128 11.8
Medium 1,490/11,457 13.0 718/7,342 9.8 2,310/18,648 12.4
Low 943/6,749 14.0 452/4,576 9.9 1,244/9,935 12.5
Very low 631/4,197 15.0 209/2,126 9.8 763/5,465 14.0
Unknown 291/2,846 10.2 182/1,854 9.8 571/5,465 10.4
* Type of sexual contact was missing for 3% (n=3,491) of persons tested for chlamydia.
** Voluntary question, answered by 56% (n=74,706) of persons tested for chlamydia. 
 
Table 3.4 Concurrent STI by gender and sexual preference among persons diagnosed with 
chlamydia, 2013.
Concurrent infection Heterosexual men MSM Women
 (N=5,201) n (%) (N=2,645) n (%) (N=7,921) n (%)
Gonorrhoea 240 (4.6) 535 (20.2) 386 (4.9)
Infectious syphilis 2 (0.0) 90 (3.4) 2 (0.0)
HIV newly diagnosed 1 (0.0) 80 (3.0) 2 (0.0)
Genital herpes 20 (0.4) 10 (0.4) 32 (0.4)
Genital warts 85 (1.6) 44 (1.7) 97 (1.2)
Hepatitis B, infectious 15 (0.3) 13 (0.5) 7 (0.1)
Hepatitis C 0 (0.0) 6 (0.2) 0 (0.0)
Table 3.5 Location of chlamydia infection by gender and sexual preference, 2013.
Location Heterosexual men MSM Women
 (N=5,201) n (%) (N=2,645) n (%) (N=7,921) n (%)
Urogenital only 5,124 (98.5) 653 (24.7) 6,217 (78.5)
Anorectal only 16 (0.3) 1,466 (55.4) 203 (2.6)
Oral only 4 (0.1) 118 (4.5) 96 (1.2)
Urogenital and anorectal 9 (0.2) 253 (9.6) 668 (8.4)
Urogenital and oral 14 (0.3) 14 (0.5) 428 (5.4)
Anorectal and oral 0 (0.0) 98 (3.7) 15 (0.2)
Urogenital and anorectal 
and oral 
0 (0.0) 32 (1.2) 123 (1.6)
Pooled samples* 34 (0.7) 11 (0.4) 171 (2.2)
* Pooled samples are samples from more than one anatomical site tested in one molecular test, so that 
location of the infection is unknown. 
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Table 3.6 Number and percentage of positive tests for chlamydia by location, gender and 
sexual preference, 2007–2013.
2008 2009 2010 2011 2012 2013
  n positive 
(%)
n positive 
(%)
n positive 
(%)
n positive 
(%)
n positive 
(%)
n positive 
(%)
Heterosexual men
Urogenital 3,343 
(10.6)
3,480 
(10.8)
3,922 
(11.3)
4,434 
(11.9)
5,052 
(13.2)
5,154 
(12.7)
Anorectal 2 
(0.8)
7 
(1.6)
13 
(2.8)
17 
(2.8)
22 
(3.3)
25 
(2.9)
 Oral 6 
(1.1)
4 
(0.5)
10 
(1.0)
11 
(0.8)
18 
(1.3)
20 
(1.2)
MSM
Urogenital 651 
(4.8)
661 
(4.1)
790 
(4.1)
852 
(3.9)
875 
(3.6)
954 
(3.5)
Anorectal 1,046 
(11.7)
1,081 
(9.5)
1,381 
(9.5)
1,537 
(9.1)
1,800 
(9.1)
1,856 
(8.2)
Oral 72 
(2.1)
81 
(1.5)
134 
(1.8)
218 
(1.2)
272 (
1.3)
264 
(1.1)
Women
Urogenital 4,385 
(10.3)
4,521 
(10.3)
5,386 
(10.7)
6,109 
(11.4)
6,736 
(11.6)
7,498 
(11.5)
Anorectal 328 
(9.4)
380 
(9.2)
439 
(9.2)
551 
(9.3)
740
 (9.5)
1,028 
(10.2)
Oral 134 
(2.3)
214 
(2.9)
239 
(2.6)
416
(2.8)
586 
(3.4)
719 
(3.3)
Footnote: Heterosexual men and women are not often tested anorectally or orally, therefore the 
fluctuation of positivity rates through the years has to be interpreted with caution. Please note that 
people can have positive tests at multiple locations.
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Figure 3.4 Total number of tests and positivity rate of chlamydia by gender and sexual 
preference, 2004–2013.
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Figure 3.5 Trends in positivity rate in heterosexuals by age group, 2004–2013.
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3.3 General practitioner
Figure 3.6 Estimated prevalence of episodes of chlamydia at GPs by gender, based on 
extrapolation from practices in the surveillance network of NIVEL-PCD, using the old method 
(2002-2011) and the new method (2010-2012).
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Table 3.7 Estimated prevalence of episodes of chlamydia per 100,000 population at GPs in the 
Netherlands by gender, based on extrapolation from the practices in the surveillance network 
of NIVEL-PCD, using the old method (2002-2011) and the new method (2010-2012).
Men Women Total
  n/100,000 n/100,000 n/100,000
Old method
2002 128 189 158
2003 135 180 157
2004 154 193 173
2005 166 176 171
2006 158 168 163
2007 153 158 155
2008 219 207 213
2009 190 202 196
2010 186 191 189
2011 211 214 212
New method
2010 252 242 247
2011 225 218 222
2012 259 288 273
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3.4 Laboratory surveillance
Figure 3.7 Number of positive tests for Chlamydia trachomatis from approximately 21 medical 
microbiology laboratories, 2000-2013.
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3.5 Lymphogranuloma venereum
Table 3.8 Characteristics of MSM diagnosed with LGV at the STI clinics, 2008–2013.
2008 2009 2010 2011 2012 2013
(N=100) (N=84*) (N=66) (N=70) (N=184) (N=106)
n (%) n (%) n (%)  n (%)  n (%) n (%)
Median age (range) 41.6 
(26–63)
41.0 
(20–61)
41 
(21-65)
40 
(21-67)
41 
(19-67)
43 
(19-69)
Dutch ethnicity 74 (74.0) 64 (97.0) 56 (84.8) 40 (57.1) 117 (63.6) 71 (67.0)
Known HIV positive 71 (71.0) 59 (89.4) 49 (74.2) 55 (78.6) 140 (76.1) 83 (78.3)
LGV with anorectal 
chlamydia infection only
96 (96.0) 75 (113.6) 58 (87.9) 53 (75.7) 153 (83.2) 97 (91.5)
LGV with urethral 
chlamydia infection only
3 (3.0) 0 (0.0) 0 (0.0) 2 (2.9) 0 (0.0) 1 (0.9)
LGV with anorectal and 
urethral chlamydia
1 (1.0) 9 (13.6) 8 (12.1) 5 (7.1) 22 (12.0) 8 (7.5)
Concurrent gonorrhoea 26  (26.0) 24 (36.4) 14 (21.2) 17 (24.3) 47 (25.5) 30 (28.3)
Concurrent  syphilis 11 (11.0) 3 (4.5) 5 (7.6) 9 (12.9) 17 (9.2) 9 (8.5)
Concurrent  new HIV 
diagnosis
2 (2.0) 2 (3.0) 1 (1.5) 2 (2.9) 9 (4.9) 2 (1.9)
*In addition one case was reported in a man with unknown sexual preference.
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Figure 3.8 Number of tests for Lymphogranuloma venereum and positivity rate at the STI 
clinics, the Netherlands, 2006–2013.
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4 
Gonorrhoea
4.1 Key points
• In 2013, 4,153 people (14.9 per cent heterosexual men, 61.2 per cent MSM and 23.9 per cent 
women) were diagnosed with gonorrhoea at STI clinics in the Netherlands.
• The overall positivity rate was stable in 2013 (3.4 per cent) compared with 2012 (3.6 per cent). 
The positivity rate was 9.3 per cent among MSM, 1.7 per cent among heterosexual men and 
1.8 per cent among women.
• While in heterosexual men the positivity rate was highest among those aged 15-19 (3.2 per 
cent), in women the positivity rate was highest among those aged 50-54 (3.0 per cent).  
Among women aged 15-19 the positivity rate was 2.8 per cent. 
• For the first time since 2008, the positivity rate decreased in both heterosexual men and 
women aged 15-24 years. 
• The positivity rate was particularly high in the following risk groups: both heterosexual men 
and MSM who were known HIV-positive (14.3 and 15.7 per cent respectively), MSM, who 
previously had an STI (14.3 per cent), MSM, who had had sexual contact with commercial sex 
workers (CSW) in the past 6 months (11.8 per cent), and heterosexual men and women of 
Surinamese (4.0 and 3.6 per cent respectively) or Dutch Antillean/Aruban (5.8 and 4.9 per 
cent respectively) descent. 
• Of the individuals diagnosed with gonorrhoea, 27.9 per cent had a chlamydia co-infection; 
1.6 per cent were newly diagnosed with HIV.
• At GPs, the number of reported gonorrhoea infections was estimated at 8,266 in 2012 (61 per 
cent men) and a clear increase was seen over the last 3 years using the new method, which 
therefore cannot directly be compared the numbers reported previously (see Chapter 2: 
Methodology). 
• To date, no resistance to ceftriaxone has been found in the Netherlands. As the MIC was 
higher than 0.125 mg/L, 2.3 per cent of the isolates for cefotaxime (also a third generation 
cephalosporin) were considered resistant. Clinical resistance (i.e. treatment failure) to third 
generation cephalosporins was not reported in 2013 or before.
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Figure 4.1 Positivity rates of gonorrhoea by region, the Netherlands, 2013.
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4.2   STI clinics: characteristics, risk groups and trends 
Table 4.1 Number of positive tests and persons tested for gonorrhoea by age, gender and 
sexual preference, 2013.
Age (years) Heterosexual men MSM Women
n positive N tested n positive N tested n positive N tested
≤14 0 3 1 2 2 69
15–19 67 2,109 74 734 188 6,811
20–24 193 14,302 405 3,814 409 25,834
25–29 132 9,099 450 4,011 178 11,091
30–34 82 4,168 398 3,515 61 4,161
35–39 42 2,276 328 3,332 43 2,303
40–44 33 1,964 286 3,408 35 2,146
45–49 34 1,557 262 3,281 36 1,816
50–54 22 1,112 203 2,407 31 1,029
≥ 55 16 1,153 134 2,935 8 623
Unknown 0 5 0 2 0 7
Total 621 37,748 2,541 27,441 991 55,890
Figure 4.2 Percentage of positive tests for gonorrhoea by age, gender and sexual                     
preference, 2013.
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Table 4.2 Number of positive tests and persons tested for gonorrhoea by ethnicity, gender and 
sexual preference, 2013.
Ethnicity Heterosexual men MSM Women
n positive N tested n positive N tested n positive N tested
The Netherlands 184 22,380 1,717 19,407 460 35,993
Turkey 29 1,063 29 346 15 602
North Africa/
Morocco
53 1,731 30 348 34 1,106
Surinam 129 3,265 76 801 130 3,636
Netherlands 
Antilles/Aruba
98 1,695 68 551 81 1,647
Sub-Saharan 
Africa
41 1,407 19 228 43 1,477
Eastern Europe 12 585 62 567 89 2,711
Latin America 19 641 105 808 30 1,566
Asia 25 1,986 121 1,409 49 2,794
Europe other 20 2,025 237 2,081 41 2,943
Else 5 286 37 328 8 445
Unknown 6 684 40 567 11 970
Natives 184 22,380 1,717 19,407 460 35,993
First generation 
migrants
215 6,920 567 5,048 251 9,411
Second generation 
migrants
215 7,690 210 2,345 266 9,441
Unknown 7 758 47 641 14 1,045
Total 621 37,748 2,541 27,441 991 55,890
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Figure 4.3 Percentage of positive tests for gonorrhoea by ethnicity, gender and sexual 
preference, 2013.
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Table 4.3 Number and percentage of positive tests and total persons tested for gonorrhoea by 
sexual behavioural characteristics, gender and sexual preference, 2013.
  Heterosexual men MSM Women
 n positive/N % n positive/ N % n positive/N %
Number of partners in past 6 months 
0 partners 1/246 0.4 4/178 2.2 1/395 0.3
1 partner 113/6,577 1.7 157/2,814 5.6 292/15,004 1.9
2 partners 159/7,434 2.1 220/3,125 7.0 211/12,212 1.7
3 or more partners 340/23,062 1.5 2,058/20,383 10.1 396/25,120 1.6
Unknown 8/429 1.9 102/941 10.8 91/3,159 2.9
Condom use if last sexual contact was steady* 
No 226/13,815 1.6 682/7,975 8.6 498/23,734 2.1
Yes 35/3,642 1.0 160/2,290 7.0 74/4,511 1.6
Unknown 1/57 1.8 9/131 6.9 1/90 1.1
Condom use if last sexual contact was casual*
No 259/13,217 2.0 963/8,905 10.8 219/16,938 1.3
Yes 95/6,331 1.5 570/6,430 8.9 173/9,233 1.9
Unknown 2/101 2.0 11/144 7.6 2/121 1.7
Previous GO/CT/syphilis in anamnesis 
No 470/31,553 1.5 1,885/22,385 8.4 710/45,936 1.5
Yes 105/2,916 3.6 595/4,169 14.3 205/5,693 3.6
Don’t know 24/1,974 1.2 26/473 5.5 33/2,454 1.3
Unknown 22/1,305 1.7 35/414 8.5 43/1,807 2.4
Previous HIV test 
No 275/17,849 1.5 231/3,389 6.8 341/22,691 1.5
Yes, positive 8/56 14.3 645/4105 15.7 1/91 1.1
Yes, negative 327/19,117 1.7 1,653/19,747 8.4 626/31,799 2.0
Yes, result unknown 3/74 4.1 7/66 10.6 3/135 2.2
Unknown 8/652 1.2 5/134 3.7 20/1,174 1.7
CSW
No 619/37,565 1.6 2,478/26,921 9.2 809/50,066 1.6
Yes, in past 6 
months
1/146 0.7 53/449 11.8 178/5,777 3.1
Unknown 1/37 2.7 10/71 14.1 4/47 8.5
Client of CSW, men
No 525/33,071 1.6 2,474/26,309 9.4
Yes, in past 6 
months
94/4,583 2.1 35/677 5.2
Unknown 2/94 2.1 32/455 7.0   
Swinger**
No 402/20,991 1.9 1,098/11,346 9.7 573/29,475 1.9
Yes 30/1,740 1.7 69/1,210 5.7 83/2,852 2.9
Unknown 0/14 0.0 5/56 8.9 8/182 4.4
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Table 4.3 (continued) Number and percentage of positive tests and total persons tested for 
gonorrhoea by sexual behavioural characteristics, gender and sexual preference, 2013.
  Heterosexual men MSM Women
 n positive/N % n positive/ N % n positive/N %
SES 
Very high 54/4,607 1.2 323/4,070 7.9 79/6,995 1.1
High 94/9,543 1.0 723/7,460 9.7 219/14,198 1.5
Medium 141/10,484 1.3 657/7,343 8.9 261/15,704 1.7
Low 157/6,363 2.5 431/4,577 9.4 168/8,794 1.9
Very low 116/4,071 2.8 210/2,126 9.9 126/5,105 2.5
Unkown 59/2,680 2.2 197/1,865 10.6 138/5,094 2.7
*  Type of sexual contact was missing for 2% (n=2,442) of persons tested for gonorrhoea.
** Voluntary question, answered by 56% (n=67,866) of persons tested for gonorrhoea. 
Table 4.4  Concurrent STI by gender and sexual preference among persons diagnosed with 
gonorrhoea, 2013.
Concurrent infection Heterosexual men MSM Women
 (N=621) n (%) (N=2,541) n (%) (N=991) n (%)
Chlamydia 240 (38.6) 535 (21.1) 386 (39.0)
Infectious syphilis 1 (0.2) 87 (3.4) 2 (0.2)
HIV newly diagnosed 3 (0.5) 62 (2.4) 3 (0.3)
Genital herpes 0 (0.0) 18 (0.7) 5 (0.5)
Genital warts 12 (1.9) 55 (2.2) 11 (1.1)
Hepatitis B, infectious 1 (0.2) 7 (0.3) 0 (0.0)
Hepatitis C 0 (0.0) 11 (0.4) 0 (0.0)
Table 4.5 Location of gonorrhoea infection by gender and sexual preference, 2013.
Location Heterosexual men MSM Women
 (N=621) n (%) (N=2,541) n (%) (N=991) n (%)
Urogenital only 576 (92.8) 267 (10.5) 531 (53.6)
Anorectal only 7 (1.1) 753 (29.6) 38 (3.8)
Oral only 30 (4.8) 704 (27.7) 156 (15.7)
Urogenital and anorectal 3 (0.5) 168 (6.6) 78 (7.9)
Urogenital and oral 4 (0.6) 112 (4.4) 115 (11.6)
Anorectal and oral 0 (0.0) 376 (14.8) 10 (1.0)
Urogenital and anorectal 
and oral 
0 (0.0) 155 (6.1) 36 (3.6)
Pooled samples* 1 (0.2) 6 (0.2) 27 (2.7)
* Pooled samples are samples from more than one anatomical site tested in one molecular test, so that 
location of infection is unknown.
70 Sexually transmitted infections, including HIV, in the Netherlands in 2013
Table 4.6 Number and percentage of positive tests for gonorrhoea by location, gender and 
sexual preference, 2006–2013.
 2006 2007 2008 2009 2010 2011 2012 2013
n 
positive
n 
positive
n 
positive
n 
positive
n 
positive
n 
positive
n 
positive
n 
positive
  (%)* (%)* (%)* (%)* (%)* (%)* (%)* (%)*
Heterosexual men
Urogenital 424 
(1.7)
429 
(1.5)
401 
(1.3)
471 
(1.5)
518 
(1.5)
684 
(1.8)
708 
(2.0)
582 
(1.5)
Anorectal 0 
(0.0)
0 
(0.0)
0 
(0.0)
2 
(0.5)
10 
(2.1)
14 
(2.3)
9 
(1.5)
10 
(1.3)
Oral 8 
(0.8)
7 
(0.8)
17
 (2.7)
11 
(1.2)
26 
(2.2)
27 
(1.8)
26 
(1.7)
34 
(2.0)
MSM
Urogenital 494 
(5.3)
430 
(4.0)
453 
(3.4)
475 
(3.0)
521 
(2.7)
610 
(2.8)
673 
(2.8)
703 
(2.6)
Anorectal 485 
(7.0)
554 
(6.7)
573 
(5.4)
698 
(5.3)
779 
(4.7)
1,024 
(5.4)
1,230 
(5.6)
1,453 
(5.8)
Oral 184 
(2.7)
209 
(2.6)
353 
(3.3)
651 
(4.8)
820 
(4.7)
999 
(4.9)
1,232 
(5.4)
1,348 
(5.1)
Women
Urogenital 326 
(1.0)
358 
(1.0)
362 
(0.9)
426 
(1.0)
546 
(1.1)
752 
(1.4)
789 
(1.6)
771 
(1.4)
Anorectal 65
 (1.0)
88 
(1.2)
81 
(1.1)
106 
(1.4)
105 
(1.2)
133 
(1.4)
128 
(1.1)
165 
(1.2)
Oral 63 
(0.8)
89 
(0.9)
121 
(1.2)
154 
(1.3)
185 
(1.4)
267 
(1.7)
269 
(1.5)
329 
(1.5)
Footnote: Heterosexual men and women are not frequently tested anorectal or oral, therefore the 
fluctuation of positivity rates through the years has to be interpreted with caution.
* Numbers do not add up to 100% since one client can have a positive test result at more than one location.
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Figure 4.4 Total number of tests and positivity rate of gonorrhoea by gender and sexual 
preference, 2004–2013.
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Figure 4.5a Trends in positivity rate for gonorrhoea in heterosexuals by age-group, 2004– 2013.
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Footnote: Since 2012, patients below the age of 25 years with no further indication criteria are not 
mandatorily tested for gonorrhoea anymore. This results in a break in trend data and these data 
therefore have to be interpreted with caution.   
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Figure 4.5b Trends in positivity rate for gonorrhoea in MSM by age-group, 2004–2013.
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Figure 4.6 Estimated prevalence of episodes of gonorrhoea at GPs by gender, based on 
extrapolation from practices in the surveillance network of NIVEL-PCD, using the old method 
(2002-2011) and the new method (2010-2012).
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Table 4.7 Estimated prevalence of episodes of gonorrhoea per 100,000 population at GPs in 
the Netherlands by gender, based on extrapolation from the practices in the surveillance 
network of NIVEL-PCD, using the old method (2002-2011) and the new method (2010-2012).
Men Women Total
  n/100,000 n/100,000 n/100,000
Old method
2002 36 19 28
2003 28 11 19
2004 26 20 23
2005 29 18 23
2006 35 10 22
2007 37 10 24
2008 33 18 26
2009 38 12 20
2010 23 10 17
2011 37 23 30
New method
2010 54 25 40
2011 64 36 50
2012 61 38 50
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4.4  Antimicrobial resistance of gonococci in the Netherlands
Figure 4.7 Gonococcal resistance (following Eucast breakpoints) in the Netherlands, 
proportion of resistant cases, 2006–2013.
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Note: In 2011, ceftriaxone, azithromycin and spectinomycin were added to the panel and testing for 
penicillin and tetracyclin became optional.
(Source: GRAS, STI clinics)
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Figure 4.8 MIC (minimum inhibitory concentration) distribution for third generation 
cephalosporin (cefotaxime), 2006–2013.
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(Source: GRAS, STI clinics)
76 Sexually transmitted infections, including HIV, in the Netherlands in 2013
77Sexually transmitted infections, including HIV, in the Netherlands in 2013
5  
Syphilis
5.1 Key points
• In 2013, the number of syphilis diagnoses was 626 (92.8 per cent MSM, 5.0 per cent hetero-
sexual men, 2.2 per cent women) at STI clinics in the Netherlands. 
• Among MSM, the syphilis positivity rate dropped from 4.3 per cent in 2007 to 2.0 per cent in 
2011. Since then, the positivity rate has stabilised at 2.1 per cent. 
• Of all infectious syphilis cases, 40.6 per cent were diagnosed in known HIV-positive MSM 
and 3.1 per cent in newly diagnosed HIV cases.
• As in previous years, the positivity rate of infectious syphilis was higher in known HIV 
positive MSM (5.8 per cent) compared with MSM who previously tested HIV-negative          
(1.4 per cent).
• Of all MSM diagnosed with syphilis, 15.5% had a co-infection with chlamydia, and 15.0% had 
a co-infection with gonorrhoea.
• Data from screening of pregnant women showed an estimated prevalence of syphilis of 
0.06% in 2012. 
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Figure 5.1 Positivity rates of infectious syphilis by region, the Netherlands, 2013.
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5.2  STI clinics: characteristics, risk groups and trends  
Table 5.1 Number of positive tests and persons tested for infectious syphilis by age, gender 
and sexual preference, 2013.
Age (years) Heterosexual men MSM Women
n positive N tested n positive N tested n positive N tested
≤14 0 3 0 2 0 61
15–19 0 1,896 8 734 1 6,110
20–24 2 13,287 57 3,815 3 23,351
25–29 5 8,908 62 4,011 1 10,798
30–34 3 4,129 86 3,508 3 4,138
35–39 4 2,267 72 3,332 2 2,285
40–44 5 1,959 80 3,401 0 2,139
45–49 5 1,551 68 3,271 3 1,805
50–54 3 1,108 74 2,404 0 1,029
≥ 55 4 1,147 74 2,929 1 622
Unknown 0 5 0 2 0 7
Total 31 36,260 581 27,409 14 52,345
Figure 5.2 Percentage of positive tests for infectious syphilis by age, gender and sexual 
preference, 2013.
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Table 5.2 Number of positive tests and persons tested for syphilis by ethnicity, gender and 
sexual preference, 2013.
Ethnicity Heterosexual men MSM Women
n positive N tested n positive N tested n positive N tested
The Netherlands 15 21,127 384 19,374 6 32,901
Turkey 4 1,061 8 347 1 594
North Africa/
Morocco
3 1,721 7 348 1 1,098
Surinam 2 3,222 22 802 3 3,582
Netherlands 
Antilles/Aruba
0 1,682 10 553 0 1,624
Eastern Europe 0 579 12 567 1 2,689
Sub-Saharan 
Africa
1 1,393 2 228 0 1,445
Latin America 1 631 38 808 1 1,555
Europe other 4 1,935 46 2,080 0 2,792
Asia 1 1,969 37 1,409 1 2,746
Unknown 0 662 7 565 0 897
Else 0 278 8 328 0 422
Natives 15 21,127 384 19,374 6 32,901
First generation 
migrants
9 6,826 140 5,048 3 9,270
Second generation 
migrants
6 7,571 48 2,348 5 9,203
Unknown 1 736 9 639 0 971
Total 31 36,260 581 27,409 14 52,345
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Figure 5.3 Percentage of positive tests for syphilis by ethnicity, gender and sexual preference, 
2013.
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Footnote: Until 2010, ethnicity was self-reported. Since 1 January 2011, ethnicity has been based on the 
country of birth of the client and client’s parents; the 2011-2013 data can therefore not be directly 
compared with previous years. 
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Table 5.3 Number and percentage of positive tests and total persons tested for gonorrhoea by 
sexual behavioural characteristics, gender and sexual preference, 2013.
  Heterosexual men MSM Women
 n positive/N % n positive/ N % n positive/N %
Number of partners in past 6 months  
0 partners 1/225 0.4 3/178 1.7 1/349 0.3
1 partner 7/5,709 0.1 47/2,809 1.7 4/12,960 0.0
2 partners 4/6,863 0.1 63/3,119 2.0 5/10,859 0.0
3 or more partners 19/23,040 0.1 445/20,365 2.2 4/25,074 0.0
Unknown 0/423 0.0 23/938 2.5 0/3,103 0.0
Condom use if last sexual contact was steady*
No 12/13,184 0.1 175/7,958 2.2 9/22,133 0.0
Yes 4/3,404 0.1 39/2,288 1.7 1/4,204 0.0
Unknown 0/55 0.0 6/131 4.6 0/84 0.0
Condom use if last sexual contact was casual 
No 12/12,924 0.1 246/8,894 2.8 2/15,965 0.0
Yes 3/6,238 0.0 88/6,427 1.4 2/8,985 0.0
Unknown 0/101 0.0 3/143 2.1 0/112 0.0
Previous GO/CT/syphilis in anamnesis 
No 20/30,443 0.1 456/22,357 2.0 10/43,279 0.0
Yes 7/2,844 0.3 115/4,166 2.8 1/5,457 0.0
Don’t know 2/1,807 0.1 6/472 1.3 1/2,045 0.0
Unknown 2/1,166 0.2 4/414 1.0 2/1,564 0.1
Previous HIV test 
No 13/16,861 0.1 62/3,387 1.8 3/20,543 0.0
Yes, positive 2/56 3.6 236/4,098 5.8 1/84 1.2
Yes, negative 16/18,864 0.1 280/19,724 1.4 9/30,823 0.0
Yes, result unknown 0/72 0.0 0/66 0.0 0/129 0.0
Unknown 0/407 0.0 3/134 2.2 1/766 0.1
CSW
No 31/36,080 0.1 562/26,891 2.1 11/46,555 0.0
Yes, in past 6 
months
0/146 0.0 17/447 3.8 3/5,747 0.1
Unknown 0/34 0.0 2/71 2.8 0/43 0.0
Client of CSW, men 
No 26/31,592 0.1 570/26,277 2.2
Yes, in past 6 
months
5/4,577 0.1 6/677 0.9
Unknown 0/91 0.0 5/455 1.1   
Swinger**
No 19/20,017 0.1 198/11,326 1.7 4/27,214 0.0
Yes 2/1,737 0.1 8/1,208 0.7 1/2,846 0.0
Unknown 0/14 0.0 1/56 1.8 1/179 0.6
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Table 5.3 (continued) Number and percentage of positive tests and total persons tested for 
gonorrhoea by sexual behavioural characteristics, gender and sexual preference, 2013.
  Heterosexual men MSM Women
 n positive/N % n positive/ N % n positive/N %
SES 
Very high 2/4,472 0.0 82/4,066 2.0 1/6,633 0.0
High 6/9,161 0.1 154/7,450 2.1 2/13,405 0.0
Medium 11/9,985 0.1 148/7,334 2.0 2/14,327 0.0
Low 4/6,126 0.1 90/4,575 2.0 4/8,284 0.1
Very low 6/3,911 0.2 52/2,124 2.4 4/4,778 0.1
Unkown 2/2,605 0.1 55/1,860 3.0 1/4,918 0.0
* Type of sexual contact was missing for 1.6% (n=1,811) of persons tested for syphilis.
** Voluntary question, answered by 56% (N=51,417) of persons tested for syphilis.
Table 5.4 Concurrent STI by gender and sexual preference among persons diagnosed with 
infectious syphilis, 2013.
Concurrent infection Heterosexual men MSM Women
 (N=31) n (%) (N=581) n (%) (N=14) n (%)
Chlamydia 2 (6.5) 90 (15.5) 2 (14.3)
Gonorrhoea 1 (3.2) 87 (15.0) 2 (14.3)
HIV newly diagnosed 0 (0.0) 18 (3.1) 0 (0.0)
Genital herpes 0 (0.0) 5 (0.9) 0 (0.0)
Genital warts 0 (0.0) 14 (2.4) 0 (0.0)
Hepatitis B, infectious 0 (0.0) 3 (0.5) 0 (0.0)
Hepatitis C 0 (0.0) 5 (0.9) 0 (0.0)
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Figure 5.4 Total number of tests and positivity rate of infectious syphilis by gender and sexual 
preference, 2004–2013.
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5.3  Antenatal Screening
Table 5.5 Syphilis prevalence estimates in pregnant women, based on test results of antenatal 
screening, 2006–2012.
Year No. of women 
screened
Positive result 
12 weeks test
Confirmed positive 
test results (%)
Prevalence esti-
mate [min, max] 
2006 185,941 320 142 (44%) 0.12 [0.08–0.13]
2007 186,137 331 181 (55%) 0.14 [0.10–0.15]
2008 190,139 359 197 (55%) 0.16 [0.10–0.17]
2009 185,219 398 257 (65%) 0.20 [0.14–0.21]
2009/10 187,478 391 272 (74%) 0.15 [0.15-0.16]
2010/11 182,199 349 211 (65%) 0.12 [0.12-0.13]
2011# 88,478 74 0.08*
2012/13 173,878  100 0.06*
Footnote 1: Terminated pregnancies (induced or spontaneous) are excluded.
Footnote 2: Since 2009, time periods of data collection range from June to June the subsequent year
Footnote 3: For the prevalence calculation, we assumed that pregnant women with a first positive test 
result without a confirmation test would be as often positive as those with a confirmation test. Up to 
2010/11 we showed a range of minimum to maximum prevalence. Minimum prevalence: number of 
confirmed positive test results divided by the total number of registered pregnant women; maximum 
prevalence: under the assumption that all pregnant women with a first positive test result without a 
confirmation test would also have a positive confirmation test.
* The prevalence was estimated using a conclusion made by the RIVM laboratory or, if this conclusion 
was unavailable, using the confirmation test.
#  Data from July-December 2011
(Source: Praeventis, RIVM)
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5.4  Blood donors
Figure 5.5 Syphilis incidence (per 100,000) among regular blood donors in the Netherlands, 
2000–2012.
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5.5  Congenital syphilis
Figure 5.6 Number of tests among neonates and young infants (<1 year) suspected of being 
infected with congenital syphilis and the number of IgM positives, 1997–2013.
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6 
HIV and AIDS
6.1 Key points
STI clinics
• In 2013, 356 individuals were newly diagnosed with HIV at STI clinics in the Netherlands (88 
per cent MSM, 4 per cent heterosexual men, and 7 per cent women).
• The positivity rate among MSM decreased from 3.0 per cent in 2008 to 1.4 per cent in 2013. 
• Among newly diagnosed HIV-positive MSM, 25 per cent had a concurrent chlamydia infec-
tion and 20 per cent a gonorrhoea infection. Among all known HIV-positive visitors, 16 per 
cent were diagnosed with chlamydia and 14 per cent with gonorrhoea.
HIV treatment centres
• A cumulative total of 21,858 HIV-patients in care were reported up to December 2013, of 
whom 90 per cent are still alive. In 2013, 1,175 new HIV-patients were reported in care; a 
small decline compared to the 1,343 in 2011. Of the newly registered patients in 2013, 829 
were newly diagnosed in 2013 (incomplete due to reporting delay). The proportion of MSM 
accounting for new HIV-patients was 70 per cent in 2013. The proportion of heterosexuals 
was 23 per cent.
• Of HIV-positive MSM in care, 38 per cent were diagnosed at STI clinics in 2013, 31 per cent at 
GPs, and 24 per cent in hospitals. Of heterosexual males, 50 per cent were diagnosed in 
hospitals, 40 per cent by GPs, and only 9 per cent at STI clinics. Of women, 49 per cent were 
diagnosed at a hospital, 23 per cent by GPs, and 16 per cent at an STI clinic.
• Of patients diagnosed in 2013, 43 per cent were diagnosed late (<350 CD4 cell counts/mm3). 
This proportion was lower for MSM (34 per cent) than for heterosexuals (62 per cent). People 
who were diagnosed in hospitals or at GPs were more often diagnosed late (66 and 41 per 
cent) compared to people diagnosed at STI clinics (26 per cent).
General practice
• Using NIVEL-PCD data, the number of registered, prevalent HIV diagnoses in general practice 
was 23,670, of which 18,004 were in men (76%) and 5,666 in women. These estimates are 
based on a relatively small number of practices for monitoring HIV, but it nevertheless shows 
that a large proportion of HIV-positives may be registered as such at general practices. 
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6.2  STI clinics: characteristics, risk groups and trends
Table 6.1 Number of positive tests and persons tested for HIV by age, gender and sexual 
preference, 2013.
Age (years) Heterosexual men MSM Women
n positive N tested n positive N tested n positive N tested
≤14 0 3 0 2 0 49
15–19 0 1,878 4 720 1 6,044
20–24 1 13,269 34 3,675 3 23,292
25–29 3 8,889 59 3,704 5 10,769
30–34 3 4,108 44 2,987 6 4,110
35–39 3 2,249 43 2,749 3 2,275
40–44 2 1,949 41 2,563 2 2,127
45–49 2 1,528 38 2,431 4 1,792
50–54 1 1,100 28 1,786 0 1,020
≥ 55 0 1,138 24 2,386 2 620
Unknown 0 5 0 2 0 7
Total 15 36,116 315 23,005 26 52,105
Figure 6.1 Percentage of positive tests for HIV by age, gender and sexual preference, 2013.
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Table 6.2 Number of positive tests and persons tested for HIV by ethnicity, gender and sexual 
preference, 2013.
Ethnicity Heterosexual men MSM Women
n positive N tested n positive N tested n positive N tested
The Netherlands 7 21,082 180 16,506 4 32,783
Turkey 0 1,058 6 310 0 589
North Africa/
Morocco
1 1,712 13 311 0 1,089
Surinam 1 3,185 21 631 5 3,554
Netherlands 
Antilles/Aruba
0 1,678 13 435 1 1,615
Sub-Saharan 
Africa
2 1,370 1 173 11 1,424
Eastern Europe 1 578 12 461 1 2,681
Latin America 1 627 16 539 3 1,548
Asia 0 1,962 17 1,189 0 2,734
Europe other 2 1,928 27 1,677 1 2,773
Else 0 275 3 247 0 420
Unknown 0 661 6 526 0 895
Natives 7 21,082 180 16,506 4 32,783
First generation 
migrants
7 6,772 99 3,923 18 9,217
Second generation 
migrants
1 7,526 30 2,018 4 9,136
Unknown 0 736 6 558 0 969
Total 15 36,116 315 23,005 26 52,105
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Figure 6.2 Percentage of positive tests for HIV by ethnicity, gender and sexual preference, 2013.
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Table 6.3 Number and percentage of positive tests and total persons tested for HIV at the STI 
clinics by sexual behavioural characteristics, gender and sexual preference, 2013.
  Heterosexual men MSM Women
 n positive/N % n positive/ N % n positive/N %
Number of partners in past 6 months 
0 partners 0/224 0.0 1/138 0.7 2/350 0.6
1 partner 4/5,698 0.1 39/2,519 1.5 11/12,881 0.1
2 partners 3/6,822 0.0 23/2,738 0.8 4/10,799 0.0
3 or more partners 8/22,952 0.0 243/16,827 1.4 6/24,982 0.0
Unknown 0/420 0.0 9/783 1.1 3/3,093 0.1
Condom use if last sexual contact was steady* 
No 6/13,156 0.1 114/6,700 1.7 12/22,023 0.1
Yes 2/3,397 0.1 21/2,005 1.0 5/4,177 0.1
Unknown 0/52 0.0 0/89 0.0 0/83 0.0
Condom use if last sexual contact was casual*
No 5/12,862 0.0 75/7,041 1.1 3/15,894 0.0
Yes 1/6,197 0.0 88/5,713 1.5 4/8,958 0.0
Unknown 0/100 0.0 5/123 4.1 0/111 0.0
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Table 6.3 (continued) Number and percentage of positive tests and total persons tested for HIV 
at the STI clinics by sexual behavioural characteristics, gender and sexual preference, 2013.
  Heterosexual men MSM Women
 n positive/N % n positive/ N % n positive/N %
Previous GO/CT/syphilis in anamnesis 
No 14/30,325 0.0 244/19,084 1.3 23/43,085 0.1
Yes 0/2,823 0.0 60/3,065 2.0 2/5,422 0.0
Don’t know 0/1,806 0.0 8/464 1.7 1/2,043 0.0
Unknown 1/1,162 0.1 3/392 0.8 0/1,555 0.0
Previous HIV test
No 9/16,823 0.1 65/3,300 2.0 11/20,475 0.1
Yes, positive 0/20 0.0 0/47 0.0 0/41 0.0
Yes, negative 6/18,794 0.0 244/19,467 1.3 14/30,696 0.1
Yes, result unknown 0/72 0.0 3/63 4.8 0/128 0.0
Unknown 0/407 0.0 3/128 2.3 1/765 0.1
CSW
No 14/35,936 0.0 305/22,570 1.4 20/46,340 0.0
Yes, in past 6 
months
1/146 0.7 9/371 2.4 6/5,722 0.1
Unknown 0/34 0.0 1/64 1.6 0/43 0.0
Client of CSW, men 
No 14/31,475 0.0 306/21,977 1.4
Yes, in past 6 
months
1/4,550 0.0 6/633 0.9
Unknown 0/91 0.0 3/395 0.8   
Swinger**
No 7/19,968 0.0 145/10,200 1.4 14/27,114 0.1
Yes 2/1,734 0.1 6/1,176 0.5 3/2,839 0.1
Unknown 0/14 0.0 0/51 0.0 0/179 0.0
SES 
Very high 2/4,449 0.0 48/3,285 1.5 1/6,607 0.0
High 5/9,131 0.1 71/6,280 1.1 4/13,370 0.0
Medium 4/9,951 0.0 66/6,247 1.1 5/14,259 0.0
Low 0/6,085 0.0 69/3,811 1.8 3/8,238 0.0
Very low 1/3,893 0.0 27/1,790 1.5 6/4,739 0.1
Unkown 3/2,607 0.1 34/1,592 2.1 7/4,892 0.1
* Type of sexual contact was missing for 1.5% (n=1,695) of persons tested for HIV.
** Voluntary question, answered by 57% (N=63,275) of persons tested for HIV.
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Table 6.4 Concurrent STI by gender and sexual preference among persons newly diagnosed 
with HIV at the STI clinics, 2013.
Concurrent infection Heterosexual men MSM Women
 (N=15) n (%) (N=315) n (%) (N=26) n (%)
Chlamydia 1 (6.7) 80 (25.4) 2 (7.7)
Gonorrhoea 3 (20.0) 62 (19.7) 3 (11.5)
Infectious syphilis 0 (0.0) 18 (5.7) 0 (0.0)
Genital herpes 0 (0.0) 1 (0.3) 0 (0.0)
Genital warts 0 (0.0) 7 (2.2) 1 (3.8)
Hepatitis B, infectious 0 (0.0) 2 (0.6) 0 (0.0)
Hepatitis C 0 (0.0) 1 (0.3) 0 (0.0)
Figure 6.3 Total number of tests and positivity rate of new HIV cases by gender and sexual 
preference, STI clinics, the Netherlands, 2004–2013.
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6.3  HIV treatment centres
6.3.1  HIV cases newly diagnosed in care in 2013 versus all registered HIV cases 
(cumulative)
Figure 6.4 Number of new HIV diagnoses per 100,000 inhabitants per PHS region, the 
Netherlands, 2013.
New HIV diagnoses
per 100.000
2.6  - 3.8
3.8  - 5.1
5.1  - 9.9
1.6 - 2.6
9.9  - 16.9
Footnote: calculations based on HIV diagnoses per PHS region. (Sources: Stichting HIV Monitoring, CBS) 
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Figure 6.5 Number of newly diagnosed HIV cases (blue; cumulative: black line) and newly 
registered HIV patients (red) by year, < 1985–2013.
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Table 6.5a Number of HIV cases diagnosed in 2013 by age and gender.
Age (years) Men (%) Women (%) Total (%)
0–14 1 (0.1) 0 (0.0) 1 (0.1)
15–19 12 (1.7) 3 (2.8) 15 (1.8)
20–24 65 (9.0) 9 (8.4) 74 (8.9)
25–29 88 (12.2) 17 (15.9) 105 (12.7)
30–39 184 (25.5) 31 (29.0) 215 (25.9)
40–49 195 (27.0) 24 (22.4) 219 (26.4)
50–59 122 (16.9) 14 (13.1) 136 (16.4)
60–69 45 (6.2) 6 (5.6) 51 (6.2)
70–79 9 (1.2) 3 (2.8) 12 (1.4)
≥ 80 1 (0.1) 0 (0.0) 1 (0.1)
Unknown 0 (0.0) 0 (0.0) 0 (0.0)
Total 722 107 829
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Table 6.5b Cumulative number of HIV cases by age (at year of diagnosis) and gender up to 2013.
Age (years) Men (%) Women (%) Total (%)
0–14 168 (1.0) 150 (3.4) 318 (1.5)
15–19 255 (1.5) 267 (6.1) 522 (2.4)
20–24 1,344 (7.7) 650 (14.8) 1,994 (9.2)
25–29 2,483 (14.3) 963 (22.0) 3,446 (15.9)
30–39 6,283 (36.2) 1,452 (33.2) 7,735 (35.6)
40–49 4,403 (25.4) 559 (12.8) 4,962 (22.8)
50–59 1,843 (10.6) 246 (5.6) 2,089 (9.6)
60–69 479 (2.8) 74 (1.7) 553 (2.5)
70–79 81 (0.5) 14 (0.3) 95 (0.4)
≥ 80 2 (0.01) 2 (0.0) 4 (0.02)
Unknown 3 (0.02) 2 (0.0) 5 (0.02)
Total 17,344 4,379 21,723
Table 6.6a Number of HIV cases diagnosed in 2013 by main reported transmission risk group 
and gender.
Transmission risk group        Men (%)      Women (%)            Total (%)
MSM 580 (80.3) - 580 (70.0)
Heterosexual contact 91 (12.6) 97 (90.7) 188 (22.7)
Injecting drug use 1 (0.1) 2 (1.9) 3 (0.4)
Blood or blood products 10 (1.4) 1 (0.9) 11 (1.3)
Mother to child 1 (0.1) 1 (0.9) 2 (0.2)
Other/unknown 39 (5.4) 6 (5.6) 45 (5.4)
Total 722 107 829
Table 6.6b Cumulative number of HIV cases by main reported transmission risk group and 
gender up to 2013.
Transmission risk group        Men (%)      Women (%)            Total (%)
MSM 12,481 (72.0) - 12,481 (57.5)
Heterosexual contact 2,985 (17.2) 3,748 (85.6) 6,733 (31.0)
Injecting drug use 545 (3.1) 204 (4.7) 749 (3.4)
Blood or blood products 199 (1.1) 105 (2.4) 304 (1.4)
Mother to child 133 (0.8) 136 (3.1) 269 (1.2)
Other/unknown 1,001 (5.8) 186 (4.2) 1,187 (5.5)
Total 17,344 4,379 21,723
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Table 6.7a Number of HIV cases diagnosed in 2013 by age and transmission risk group.
Age (years) MSM Heterosexual contact Other/ unknown*
 n (%) n (%) n (%)
0–14 0 (0.0) 0 (0.0) 1 (1.6)
15–19 10 (1.7) 2 (1.1) 3 (4.9)
20–24 58 (10.0) 14 (7.4) 2 (3.3)
25–29 77 (13.3) 23 (12.2) 5 (8.2)
30–39 146 (25.2) 52 (27.7) 17 (27.9)
40–49 153 (26.4) 47 (25.0) 19 (31.1)
50–59 94 (16.2) 33 (17.6) 9 (14.8)
60–69 35 (6.0) 12 (6.4) 4 (6.6)
70–79 7 (1.2) 5 (2.7) 0 (0.0)
≥ 80 0 (0.0) 0 (0.0) 1 (1.6)
Unknown 0 (0.0) 0 (0.0) 0 (0.0)
Total 580 188 61
Table 6.7b Cumulative number of HIV cases by age and transmission risk group up to 2013.
Age 
(years)
MSM Hetero-
sexual 
contact
Injecting 
drug use
Blood or 
blood 
products*
Mother to 
child
Other/ 
unknown
 n (%) n (%) n (%) n (%) n (%) n (%)
0–14 3 
(0.02)
11 
(0.2)
1 
(0.1)
30 
(9.9)
258 
(95.9)
15
 (1.3)
15–19 158 
(1.3)
291 
(4.3)
23 
(3.1)
19 
(6.3)
4 
(1.5)
27 
(2.3)
20–24 1,002 
(8.0)
766 
(11.4)
100 
(13.4)
34 
(11.2)
1 
(0.4)
91
 (7.7)
25–29 1,870 
(15.0)
1,195 
(17.7)
157 
(21.0)
42 
(13.8)
2 
(0.7)
180 
(15.2)
30–39 4,562 
(36.6)
2,373 
(35.2)
304 
(40.6)
89 
(29.3)
1 
(0.4)
406 
(34.2)
40–49 3,259 
(26.1)
1,252 
(18.6)
147 
(19.6)
43 
(14.1)
0 
(0.0)
261 
(22.0)
50–59 1,285 
(10.3)
611 
(9.1)
15 
(2.0)
25 
(8.2)
0 
(0.0)
153 
(12.9)
60–69 297 
(2.4)
196 
(2.9)
2 
(0.3)
17 
(5.6)
0
 (0.0)
41 
(3.5)
70–79 45 (0.4) 34 (0.5) 0 (0.0) 4 (1.3) 0 (0.0) 12 (1.0)
≥ 80 0 (0.0) 3 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.1)
Unknown 0 (0.0) 1 (0.0) 0 (0.0) 1 (0.3) 3 (1.1) 0 (0.0)
Total 12,481 6,733 695 304 269 1,187
*Including needle stick injury.   
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Table 6.8a Number of HIV cases diagnosed in 2013 by region of origin and transmission risk 
group.
Ethnicity MSM Heterosexual contact Other/ unknown
 n (%) n (%) n (%)
The Netherlands 442 (76.2) 88 (46.8) 36 (59.0)
Western Europe 29 (5.0) 7 (3.7) 1 (1.6)
Central Europe 19 (3.3) 3 (1.6) 4 (6.6)
Eastern Europe 2 (0.3) 3 (1.6) 2 (3.3)
Sub-Saharan Africa 3 (0.5) 54 (28.7) 9 (14.8)
Caribbean 21 (3.6) 7 (3.7) 1 (1.6)
Latin America 27 (4.7) 14 (7.4) 4 (6.6)
North America 1 (0.2) 0 (0.0) 0 (0.0)
North Africa and 
Middle East 
15 (2.6) 4 (2.1) 3 (4.9)
Australia and Pacific 4 (0.7) 1 (0.5) 0 (0.0)
South (East) Asia 16 (2.8) 7 (3.7) 1 (1.6)
Unknown 1 (0.2) 0 (0.0) 0 (0.0)
Total 580 188 61
Table 6.8b Cumulative number of HIV cases by transmission risk group and five most common 
regions of origin up to 2013.
Age (years) MSM Hetero-
sexual 
contact
Injecting 
drug use
Blood or 
blood 
products*
Mother 
to child
Other/ 
unknown
 n (%) n (%) n (%) n (%) n (%) n (%)
The Netherlands 8,938 
(71.6)
2,112 
(31.4)
449 
(59.9)
139 
(45.7)
106 
(39.4)
501 
(42.2)
Sub-Saharan 
Africa
171 
(1.4)
2,786 
(41.4)
8 
(1.1)
89 
(29.3)
129 
(48.0)
301 
(25.4)
Surinam 324 
(2.6)
539 
(8.0)
20 
(2.7)
9 
(3.0)
2 
(0.7)
44 
(3.7)
Neth. Antilles/
Aruba
127 
(1.0)
70 
(1.0)
6 
(0.8)
0 
(0.0)
2 
(0.7)
6 
(0.5)
Western Europe 962 
(7.7)
211 
(3.1)
142 
(19.0)
12 
(3.9)
6 
(2.2)
105 
(8.8)
Other/unknown 1,959 
(15.7)
1,015 
(15.1)
124 
(16.6)
55 
(18.1)
24 
(8.9)
230 
(19.4)
Total 12,481 6,733 695 304 269 1,187
* Including needle stick injury.
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Table 6.8c Number of HIV cases diagnosed in 2013 by test location and transmission risk 
group.
Test location MSM Heterosexual men Women
 n (%) n (%) n (%)
PHS/STI center 219 (37.8) 8 (8.8) 15 (15.5)
Hospital 141 (24.3) 45 (49.5) 47 (48.5)
General practitioner 181 (31.2) 36 (39.6) 22 (22.7)
Pregnancy screening 0 (0.0) 0 (0.0) 8 (8.2)
Other 39 (6.7) 2 (2.2) 5 (5.2)
Total 580 91 97
Figure 6.6 Number of HIV cases by age group (left axis: 20–49, right axis: 0–19 and 50+) and 
year of diagnosis, 1996–2013. 
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Figure 6.7 Proportion of annual HIV cases in care by transmission risk group and year of 
diagnosis, 1996–2013.
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Figure 6.8a Reported country of infection of MSM by year of diagnosis, 2002–2013.
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Figure 6.8b Reported country of infection of heterosexuals by year of diagnosis, 2002–2013.
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Figure 6.9a Proportion of low CD4 count (<350/mm3) at diagnosis by transmission risk group, 
1996–2013.
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Figure 6.9b Proportion of low CD4 count (<350/mm3) at diagnosis by region of origin (hete-
rosexuals only), 1996–2013.
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6.3.2 AIDS cases and deaths among HIV patients
Table 6.9 Number (per year and cumulative) of AIDS diagnoses and deaths among HIV 
patients, 1983–2013.
Year AIDS diagnoses AIDS diagnoses Deaths Deaths
 (per year) (cumulative) (per year) (cumulative)
1983 22 22 6 6
1984 31 53 16 22
1985 65 118 30 52
1986 137 255 63 115
1987 245 500 106 221
1988 325 825 135 356
1989 391 1,216 202 558
1990 419 1,635 269 827
1991 450 2,085 294 1,121
1992 510 2,595 412 1,533
1993 481 3,076 427 1,960
1994 494 3,570 444 2,404
1995 533 4,103 439 2,843
1996 459 4,562 327 3,170
1997 337 4,899 184 3,354
1998 238 5,137 136 3,490
1999 235 5,372 137 3,627
2000 247 5,619 132 3,759
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Table 6.9 (continued) Number (per year and cumulative) of AIDS diagnoses and deaths among 
HIV patients, 1983–2013.
Year AIDS diagnoses AIDS diagnoses Deaths Deaths
 (per year) (cumulative) (per year) (cumulative)
2001 261 5,880 128 3,887
2002 299 6,179 125 4,012
2003 298 6,477 144 4,156
2004 289 6,766 144 4,300
2005 356 7,122 142 4,442
2006 287 7,409 122 4,564
2007 299 7,708 153 4,717
2008 272 7,980 153 4,870
2009 266 8,246 160 5,030
2010 284 8,530 131 5,161
2011 221 8,751 150 5,311
2012 244 8,995 158 5,469
2013 155 9,150 124 5,593
(Sources: deaths among HIV patients: < 2002: Statistics Netherlands, CBS, ≥ 2002: data from the Stichting 
HIV Monitoring. Sources AIDS cases: < 1999: Health Inspectorate, ≥ 1999: Stichting HIV Monitoring, 2013 
incomplete)
Figure 6.10 Number of AIDS cases and deaths among HIV patients, 1983–2013.
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Table 6.10 Number of AIDS patients by year of AIDS diagnosis and transmission risk group, 
≤1987–2013.
Year of  
diagnosis
MSM Hetero-
sexual 
contact
Injecting 
drug use
Blood and 
blood 
contacts
Mother to 
child
Other/ 
unknown
 n (%) n (%) n (%) n (%) n (%) n (%)
≤ 1987 424 (84.8) 26 (5.2) 28 (5.6) 18 (3.6) 3 (0.6) 1 (0.2)
1988 250 (76.9) 18 (5.5) 39 (12.0) 13 (4.0) 2 (0.6) 3 (0.9)
1989 305 (78.0) 33 (8.4) 36 (9.2) 11 (2.8) 1 (0.3) 5 (1.3)
1990 318 (75.9) 34 (8.1) 42 (10.0) 17 (4.1) 3 (0.7) 5 (1.2)
1991 335 (74.4) 46 (10.2) 43 (9.6) 19 (4.2) 2 (0.4) 5 (1.1)
1992 376 (73.7) 51 (10.0) 60 (11.8) 12 (2.4) 2 (0.4) 9 (1.8)
1993 317 (65.9) 80 (16.6) 61 (12.7) 8 (1.7) 3 (0.6) 12 (2.5)
1994 314 (63.6) 94 (19.0) 65 (13.2) 14 (2.8) 2 (0.4) 5 (1.0)
1995 314 (58.9) 116 (21.8) 74 (13.9) 7 (1.3) 9 (1.7) 13 (2.4)
1996 299 (65.1) 95 (20.7) 50 (10.9) 5 (1.1) 2 (0.4) 8 (1.7)
1997 174 (51.6) 104 (30.9) 43 (12.8) 3 (0.9) 2 (0.6) 11 (3.3)
1998 116 (48.7) 78 (32.8) 27 (11.3) 1 (0.4) 3 (1.3) 13 (5.5)
1999 117 (49.8) 80 (34.0) 14 (6.0) 6 (2.6) 4 (1.7) 14 (6.0)
2000 105 (42.5) 102 (41.3) 16 (6.5) 5 (2.0) 2 (0.8) 17 (6.9)
2001 105 (40.2) 110 (42.1) 12 (4.6) 6 (2.3) 7 (2.7) 21 (8.0)
2002 114 (38.1) 139 (46.5) 10 (3.3) 4 (1.3) 3 (1.0) 29 (9.7)
2003 116 (38.9) 123 (41.3) 14 (4.7) 8 (2.7) 4 (1.3) 33 (11.1)
2004 118 (40.8) 115 (39.8) 12 (4.2) 3 (1.0) 2 (0.7) 39 (13.5)
2005 152 (42.7) 140 (39.3) 25 (7.0) 5 (1.4) 1 (0.3) 33 (9.3)
2006 124 (43.2) 108 (37.6) 10 (3.5) 5 (1.7) 3 (1.0) 37 (12.9)
2007 136 (45.5) 110 (36.8) 13 (4.3) 4 (1.3) 4 (1.3) 32 (10.7)
2008 131 (48.2) 100 (36.8) 7 (2.6) 6 (2.2) 1 (0.4) 27 (9.9)
2009 134 (50.4) 104 (39.1) 8 (3.0) 1 (0.4) 2 (0.8) 17 (6.4)
2010 127 (44.7) 120 (42.3) 6 (2.1) 3 (1.1) 5 (1.8) 23 (8.1)
2011 108 (48.9) 79 (35.7) 7 (3.2) 1 (0.5) 2 (0.9) 24 (10.9)
2012 119 (48.8) 93 (38.1) 4 (1.6) 1 (0.4) 1 (0.4) 26 (10.7)
2013 78 (50.3) 48 (31.0) 2 (1.3) 3 (1.9) 0 (0.0) 24 (15.5)
Total 5,326 (62.4) 2,346 (27.5) 728 (8.5) 189 (2.2) 75 (0.9) 486 (5.7)
(Sources: < 1999: Health Inspectorate, 1999–2010: Stichting HIV Monitoring, 2013 incomplete)
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Table 6.11 Number of deaths among HIV/AIDS patients by year of death and transmission risk 
group, 2002–2013.
Year of 
death
MSM Hetero-
sexual 
contact
Injecting 
drug use
Blood or 
blood 
products*
Other/ 
unknown
 n (%) n (%) n (%) n (%) n (%)
2002 54 (43.2) 30 (24.0) 18 (14.4) 4 (3.2) 19 (15.2)
2003 55 (38.2) 35 (24.3) 34 (23.6) 4 (2.8) 16 (11.1)
2004 82 (56.9) 37 (25.7) 17 (11.8) 1 (0.7) 7 (4.9)
2005 62 (43.7) 41 (28.9) 18 (12.7) 1 (0.7) 20 (14.1)
2006 58 (47.5) 28 (23.0) 17 (13.9) 2 (1.6) 17 (13.9)
2007 82 (53.6) 34 (22.2) 19 (12.4) 3 (2.0) 15 (9.8)
2008 78 (51.0) 41 (26.8) 22 (14.4) 1 (0.7) 11 (7.2)
2009 82 (51.3) 40 (25.0) 19 (11.9) 4 (2.5) 15 (9.4)
2010 64 (48.9) 32 (24.4) 15 (11.5) 4 (3.1) 16 (12.2)
2011 75 (50.0) 45 (30.0) 13 (8.7) 0 (0.0) 17 (11.3)
2012 87 (55.1) 37 (23.4) 18 (11.4) 1 (0.6) 15 (9.5)
2013 69 (55.6) 32 (25.8) 12 (9.7) 1 (0.8) 10 (8.1)
Footnote: mother to child transmission did not lead to death. 
* Including needle stick injury (Source: Stichting HIV Monitoring)
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6.4  Other sources
6.4.1 Antenatal screening
Table 6.12 HIV prevalence estimates in pregnant women, based on test results of antenatal 
screening, 2006–2012.
Year No. of women 
screened
Positive result 
12 weeks test
Confirmed positive 
test results (%)
Prevalence estimate 
[min, max] 
2006 185,602 342 81 (24%) 0.05 [0.04–0.08]
2007 185,791 327 90 (27%) 0.05 [0.05–0.05]
2008 189,765 289 68 (24%) 0.05 [0.04–0.07]
2009 185,219 324 100 (31%) 0.05 [0.05–0.07]
2009/10 187,309 336 109 (34%) 0.06 [0.06-0.07]
2010/11 182,071 301 89 (31%) 0.05 [0.05-0.06]
2011# 88,425 52 0.06*
2012/13 173,802  114 0.07*
Footnote 1: Terminated pregnancies (induced or spontaneous) are excluded.
Footnote 2: Since 2009, time periods of data collection range from June to June the subsequent year.
Footnote 3: For the prevalence calculation, we assumed that pregnant women with a first positive test 
result without a confirmation test would be as often positive as those with a confirmation test. Up to 
2010/11, we showed a range of minimum to maximum prevalence. Minimum prevalence: number of 
confirmed positive test results divided by the total number of registered pregnant women; maximum 
prevalence: under the assumption that all pregnant women with a first positive test result without a 
confirmation test would also have a positive confirmation test.
* The prevalence was estimated using a conclusion made by the RIVM laboratory or, if this conclusion 
was unavailable, using the confirmation test. 
# Data from July-December 2011   
(Source: Praeventis, RIVM)
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6.4.2 Blood donors
Figure 6.11 HIV incidence (per 100,000) among regular blood donors in the Netherlands, 
2000–2012.
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(Source: Sanquin, 2013 not available yet)
6.4.3 HIV incidence in MSM and IDU in the Amsterdam Cohort Studies
Figure 6.12 Yearly HIV incidence among MSM in Amsterdam Cohort Studies, 1985–2013.
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Figure 6.13 Yearly HIV incidence among IDUs (≤ 30 years at entry) in Amsterdam Cohort 
Studies, 1986–2013.
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6.5 General Practice
Figure 6.14 National estimate of the number of prevalent HIV-positive men and women 
registered at GPs, based on data from the practices reporting to NIVEL-PCD between 2010-2012.
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7 
Genital warts
7.1  Key points
• In 2013, the number of genital warts diagnoses was 2,057 (42.9 per cent heterosexual men, 
22.5 per cent MSM, 34.6 per cent women) at STI clinics in the Netherlands. 
• The overall positivity rate continued to decrease from 2.9 per cent in 2009 to 1.5 per cent in 
2013. The positivity rate was higher among heterosexual men (2.2 per cent) than among 
women (1.1 per cent) and MSM (1.7 per cent).
• Among heterosexual men, MSM and women, the positivity rate of genital warts by ethnicity 
was highest among those of North African descent.
• Among heterosexual men and women diagnosed with genital warts, chlamydia was the 
most common co-infection (9.6 and 13.6 per cent respectively), whereas gonorrhoea was the 
most frequently diagnosed co-infection among MSM (11.9 per cent).
• In general practice, the number of cases increased gradually over the last years until 2011 (old 
method). Using the new method, the number of people with one or more episodes of genital 
warts was estimated at 38,483 (52 per cent in men) in 2012 and was stable compared to 2010 
and 2011. The numbers of episodes of genital warts were higher using the new method than 
the numbers previously reported using the old method (probably due to stricter definitions 
of the end of an episode and start of a new episode; see Chapter 2: Methodology). 
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Figure 7.1 Positivity rates of genital warts by region, the Netherlands, 2013.
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7.2  STI clinics: characteristics, risk groups and trends
Table 7.1 Number of people diagnosed with genital warts and number of STI consultations by 
age, gender and sexual preference, 2013.
Age (years) Heterosexual men MSM Women
n 
positive
N 
consultations
n 
positive
N 
consultations
n 
positive
N 
consultations
≤ 14 0 8 0 2 2 83
15–19 40 2,567 13 738 92 8,559
20–24 336 16,615 92 3,831 377 32,643
25–29 259 9,388 63 4,023 130 11,699
30–34 103 4,185 68 3,518 46 4,174
35–39 47 2,291 65 3,336 21 2,309
40–44 36 1,974 47 3,414 16 2,149
45–49 20 1,565 45 3,284 14 1,823
50–54 22 1,117 30 2,412 9 1,030
≥ 55 20 1,157 40 2,937 4 626
Unknown 0 5 0 2 0 9
Total 883 40,872 463 27,497 711 65,104
Figure 7.2 Positivity rate of genital warts by age, gender and sexual preference, 2013.
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Table 7.2 Number of people diagnosed with genital warts and number of STI consultations by 
ethnicity, gender and sexual preference, 2013.
Ethnicity Heterosexual men MSM Women
n 
positive
N consul- 
tations
n 
positive
N consul- 
tations
n 
positive
N consul- 
tations
The Netherlands 507 25,100 308 19,443 519 44,286
Turkey 22 1,078 8 347 6 620
North Africa/Morocco 67 1,748 13 348 14 1,124
Surinam 58 3,273 22 803 28 3,671
Netherlands Antilles/
Aruba
30 1,706 8 553 19 1,660
Sub-Saharan Africa 26 1,418 4 228 9 1,491
Eastern Europe 20 600 11 567 24 2,734
Latin America 17 646 20 810 9 1,578
Asia 42 2,020 20 1,415 31 2,858
Europe other 54 2,144 38 2,083 37 3,244
Else 12 303 5 328 6 516
Unknown 28 836 6 572 9 1,322
Natives 507 25,100 308 19,443 519 44,286
First generation 
migrants
145 7,006 96 5,057 81 9,580
Second generation 
migrants
202 7,854 52 2,351 101 9,839
Unknown 29 912 7 646 10 1,399
Total 883 40,872 463 27,497 711 65,104
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Figure 7.3 Positivity rate of genital warts by ethnicity, gender and sexual preference, 2013.
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Table 7.3 Number of people diagnosed with genital warts and number of STI consultations by 
sexual behavioural characteristics, gender and sexual preference, 2013.
  Heterosexual men MSM Women
 n positive/N 
consultations
%
 
n positive/ N
consultations 
% n positive/N
consultations 
%
Number of partners in past 6 months
0 partners 14/301 4.7 3/182 1.6 10/550 1.8
1 partner 234/8,075 2.9 47/2,833 1.7 246/19,487 1.3
2 partners 175/8,838 2.0 58/3,130 1.9 167/16,547 1.0
3 or more partners 443/23,178 1.9 345/20,397 1.7 268/25,262 1.1
Unknown 17/480 3.5 10/955 1.0 20/3,258 0.6
Condom use if last sexual contact was steady*
No 397/15,214 2.6 143/7,991 1.8 330/27,510 1.2
Yes 69/4,136 1.7 44/2,295 1.9 56/5,248 1.1
Unknown 2/66 3.0 3/131 2.3 0/105 0.0
Condom use if last sexual contact was casual*
No 271/14,008 1.9 149/8,920 1.7 224/19,977 1.1
Yes 129/6,582 2.0 114/6,439 1.8 97/9,961 1.0
Unknown 1/110 0.9 1/145 0.7 0/153 0.0
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Table 7.3 (continued) Number of people diagnosed with genital warts and number of STI 
consultations by sexual behavioural characteristics, gender and sexual preference, 2013.
  Heterosexual men MSM Women
 n positive/N 
consultations
%
 
n positive/ N
consultations 
% n positive/N
consultations 
%
Previous GO/CT/syphilis in anamnesis 
No 755/33,975 2.2 380/22,424 1.7 609/53,397 1.1
Yes 69/3,114 2.2 78/4,178 1.9 69/6,419 1.1
Don’t know 35/2,370 1.5 2/476 0.4 25/3,221 0.8
Unknown 24/1,413 1.7 3/419 0.7 8/2,067 0.4
Previous HIV test
No 375/20,268 1.9 59/3,402 1.7 321/29,014 1.1
Yes, positive 0/58 0.0 93/4,110 2.3 1/95 1.1
Yes, negative 499/19,764 2.5 307/19,779 1.6 381/34,577 1.1
Yes, result unknown 1/75 1.3 1/66 1.5 1/140 0.7
Unknown 8/707 1.1 3/140 2.1 7/1,278 0.5
CSW
No 876/40,677 2.2 445/26,975 1.6 684/59,258 1.2
Yes, in past 6 
months
7/149 4.7 15/450 3.3 27/5,781 0.5
Unknown 0/46 0.0 3/72 4.2 0/65 0.0
Client of CSW, men
No 788/36,128 2.2 447/26,363 1.7
Yes, in past 6 
months
94/4,638 2.0 10/678 1.5
Unknown 1/106 0.9 6/456 1.3
Swinger**
No 468/23,017 2.0 166/11,382 1.5 365/34,399 1.1
Yes 24/1,742 1.4 17/1,210 1.4 22/2,857 0.8
Unknown 0/14 0.0 0/56 0.0 3/185 1.6
SES
Very high 100/5,008 2.0 68/4,077 1.7 99/8,390 1.2
High 227/10,522 2.2 131/7,470 1.8 197/17,150 1.1
Medium 254/11,484 2.2 115/7,358 1.6 217/18,664 1.2
Low 145/6,771 2.1 92/4,587 2.0 109/9,952 1.1
Very low 87/4,204 2.1 26/2,131 1.2 49/5,472 0.9
Unkown 70/2,883 2.4 31/1,874 1.7 40/5,476 0.7
* Type of sexual contact was missing for 3 per cent (n=3,510) of persons with an STI consultation.
** Voluntary question, answered by 53 per cent (n=70,977) of persons with an STI consultation.
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Table 7.4 Concurrent STI by gender and sexual preference among people diagnosed with 
genital warts, 2013.
Concurrent infection Heterosexual men MSM Women
 (N=883) n (%) (N=463) n (%) (N=711) n (%)
Chlamydia 85 (9.6) 44 (9.5) 97 (13.6)
Gonorrhoea 12 (1.4) 55 (11.9) 11 (1.5)
Infectious syphilis 0 (0.0) 14 (3.0) 0 (0.0)
HIV newly diagnosed 0 (0.0) 7 (1.5) 1 (0.1)
Genital herpes 5 (0.6) 3 (0.6) 7 (1.0)
Hepatitis B, infectious 1 (0.1) 0 (0.0) 0 (0.0)
Hepatitis C 0 (0.0) 1 (0.2) 0 (0.0)
Figure 7.4 Total number of STI consultations and positivity rate of genital warts by gender and 
sexual preference, 2004–2013.
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7.3  General practitioner
Figure 7.5 Estimated prevalence of patients with one or more episodes of genital warts seen by 
GPs annually by gender, based on extrapolation from practices in the surveillance network of 
NIVEL-PCD, using the old method (2002-2011) and the new method (2010-2012).
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Table 7.5 Estimated prevalence of persons with one or more episodes of genital warts per 100,000 
population at GPs in the Netherlands by gender, based on extrapolation from practices in the 
surveillance network of NIVEL-PCD, using the old method (2002-2011) and the new method 
(2010-2012).
Men Women Total
  n/100,000 n/100,000 n/100,000
Old method
2002 71 77 74
2003 65 68 66
2004 80 79 80
2005 94 83 89
2006 83 107 95
2007 87 108 98
2008 122 123 122
2009 140 122 131
2010 139 118 129
2011 146 142 144
New method
2010 226 220 223
2011 229 215 222
2012 244 217 230
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8
Genital herpes
8.1  Key points
• In 2013, the number of genital herpes diagnoses was 612 (33.2 per cent heterosexual men, 
17.1 per cent MSM, and 49.7 per cent women) at STI clinics in the Netherlands. 
• In 2013, the positivity rate among women was similar to the positivity rate in 2012 (0.5 per 
cent). Among heterosexual men and MSM, the positivity rate dropped by 0.1 per cent to 0.5 
per cent and 0.4 per cent respectively in 2013. The positivity rate was the highest among 
known HIV-positive heterosexual men (3.4 per cent).
• Among heterosexual men and women diagnosed with genital herpes, chlamydia was the 
most common co-infection (9.9 and 10.5 per cent respectively), whereas gonorrhoea was the 
most frequently diagnosed co-infection among MSM (17.1 per cent).
• In general practice, a gradual increase was observed in the number of genital herpes 
infections in both women and in men over the years until 2011 (old method). Using the new 
method, the number of people with one or more episodes of genital herpes was estimated 
at 22,834 (26 per cent in men) in 2012 and was stable compared to 2010 and 2011. Because of 
changes in general practice surveillance, the numbers reported using the new method were 
higher than the numbers previously reported using the old method (probably due to stricter 
definitions of the end of an episode and start of a new episode; see Chapter 2: 
Methodology). 
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Figure 8.1 Positivity rates of genital herpes by region, the Netherlands, 2013.
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8.2  STI clinics: characteristics, risk groups and trends
Table 8.1 Number of people diagnosed with genital herpes and number of STI consultations 
by age, gender and sexual preference, 2013.
Age (years) Heterosexual men MSM Women
n 
positive
N 
consultations
n 
positive
N 
consultations
n 
positive
N 
consultations
≤ 14 0 8 0 2 0 83
15–19 9 2,567 1 738 45 8,559
20–24 51 16,615 7 3,831 117 32,643
25–29 47 9,388 27 4,023 69 11,699
30–34 35 4,185 14 3,518 27 4,174
35–39 21 2,291 10 3,336 21 2,309
40–44 15 1,974 19 3,414 8 2,149
45–49 11 1,565 8 3,284 10 1,823
50–54 6 1,117 11 2,412 6 1,030
≥ 55 8 1,157 8 2,937 1 626
Unknown 0 5 0 2 0 9
Total 203 40,872 105 27,497 304 65,104
Figure 8.2 Positivity rate of genital herpes by age, gender and sexual preference, 2013.
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Table 8.2 Number of people diagnosed with genital herpes and number of STI consultations 
by ethnicity, gender and sexual preference, 2013.
Ethnicity Heterosexual men MSM Women
n 
positive
N consul- 
tations
n 
positive
N consul- 
tations
n 
positive
N consul- 
tations
The Netherlands 107 25,100 66 19,443 189 44,286
Turkey 4 1,078 1 347 2 620
North Africa/Morocco 10 1,748 1 348 5 1,124
Surinam 31 3,273 5 803 21 3,671
Netherlands Antilles/
Aruba
12 1,706 3 553 17 1,660
Sub-Saharan Africa 7 1,418 0 228 4 1,491
Eastern Europe 3 600 2 567 11 2,734
Latin America 5 646 7 810 6 1,578
Asia 8 2,020 7 1,415 18 2,858
Europe other 13 2,144 10 2,083 22 3,244
Else 1 303 2 328 5 516
Unknown 2 836 1 572 4 1,322
Natives 107 25,100 66 19,443 189 44,286
First generation 
migrants
39 7,006 25 5,057 60 9,580
Second generation 
migrants
55 7,854 11 2,351 51 9,839
Unknown 2 912 3 646 4 1,399
Total 203 40,872 105 27,497 304 65,104
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Figure 8.3 Positivity rate of genital herpes by ethnicity, gender and sexual preference, 2013.
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Table 8.3 Number of people diagnosed with genital herpes and number of STI consultations 
by sexual behavioural characteristics, gender and sexual preference, 2013.
  Heterosexual men MSM Women
 n positive/N 
consultations
%
 
n positive/ N
consultations 
% n positive/N
consultations 
%
Number of partners in past 6 months 
0 partners 1/301 0.3 0/182 0.0 1/550 0.2
1 partner 52/8,075 0.6 8/2,833 0.3 111/19,487 0.6
2 partners 48/8,838 0.5 14/3,130 0.4 81/16,547 0.5
3 or more partners 100/23,178 0.4 83/20,397 0.4 98/25,262 0.4
Unknown 2/480 0.4 0/955 0.0 13/3,258 0.4
Condom use if last sexual contact was steady*
No 101/15,214 0.7 27/7,991 0.3 159/27,510 0.6
Yes 9/4,136 0.2 10/2,295 0.4 21/5,248 0.4
Unknown 1/66 1.5 0/131 0.0 0/105 0.0
Condom use if last sexual contact was casual*
No 68/14,008 0.5 39/8,920 0.4 81/19,977 0.4
Yes 22/6,582 0.3 25/6,439 0.4 36/9,961 0.4
Unknown 1/110 0.9 2/145 1.4 1/153 0.7
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Table 8.3 (continued) Number of people diagnosed with genital herpes and number of STI 
consultations by sexual behavioural characteristics, gender and sexual preference, 2013.
  Heterosexual men MSM Women
 n positive/N 
consultations
%
 
n positive/ N
consultations 
% n positive/N
consultations 
%
Previous GO/CT/syphilis in anamnesis 
No 175/33,975 0.5 86/22,424 0.4 259/53,397 0.5
Yes 20/3,114 0.6 18/4,178 0.4 29/6,419 0.5
Don’t know 5/2,370 0.2 0/476 0.0 10/3,221 0.3
Unknown 3/1,413 0.2 1/419 0.2 6/2,067 0.3
Previous HIV test
No 67/20,268 0.3 5/3,402 0.1 120/29,014 0.4
Yes, positive 2/58 3.4 35/4,110 0.9 0/95 0.0
Yes, negative 131/19,764 0.7 65/19,779 0.3 178/34,577 0.5
Yes, result unknown 0/75 0.0 0/66 0.0 1/140 0.7
Unknown 3/707 0.4 0/140 0.0 5/1,278 0.4
CSW
No 202/40,677 0.5 102/26,975 0.4 286/59,258 0.5
Yes, in past 6 
months
0/149 0.0 2/450 0.4 17/5,781 0.3
Unknown 1/46 2.2 1/72 1.4 1/65 1.5
Client of CSW, men
No 178/36,128 0.5 101/26,363 0.4
Yes, in past 6 
months
24/4,638 0.5 1/678 0.1
Unknown 1/106 0.9 3/456 0.7
Swinger**
No 94/22,275 0.4 33/11,382 0.3 171/34,399 0.5
Yes 4/1,721 0.2 1/1,210 0.1 9/2,857 0.3
Unknown 0/45 0.0 0/56 0.0 1/185 0.5
SES
Very high 26/5,008 0.5 17/4,077 0.4 40/8,390 0.5
High 51/10,522 0.5 38/7,470 0.5 70/17,150 0.4
Medium 49/11,484 0.4 27/7,358 0.4 79/18,664 0.4
Low 36/6,771 0.5 11/4,587 0.2 64/9,952 0.6
Very low 27/4,204 0.6 1/2,131 0.0 33/5,472 0.6
Unkown 14/2,883 0.5 11/1,874 0.6 18/5,476 0.3
* Type of sexual contact was missing for 3 per cent (n= 3,510) of persons with an STI consultation.
** Voluntary question, answered by 53 per cent (n=70,977) of persons with an STI consultation.
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Table 8.4 Concurrent STI by gender and sexual preference among people diagnosed with 
genital herpes, 2013.
Concurrent infection Heterosexual men MSM Women
 (N=203) n (%) (N=105) n (%) (N=304) n (%)
Chlamydia 20 (9.9) 10 (9.5) 32 (10.5)
Gonorrhoea 0 (0.0) 18 (17.1) 5 (1.6)
Infectious syphilis 0 (0.0) 5 (4.8) 0 (0.0)
HIV newly diagnosed 0 (0.0) 1 (1.0) 0 (0.0)
Genital warts 5 (2.5) 3 (2.9) 7 (2.3)
Hepatitis B, infectious 0 (0.0) 0 (0.0) 0 (0.0)
Hepatitis C 0 (0.0) 0 (0.0) 0 (0.0)
Figure 8.4 Total number of STI consultations and positivity rate of genital herpes by gender 
and sexual preference, 2004–2013.
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Footnote: Positivity rate was estimated by dividing the number of genital herpes diagnoses by the total 
number of STI consultations
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8.3  General practitioner
Figure 8.5 Estimated prevalence of patients with one or more episodes of genital herpes at 
GPs by gender, based on extrapolation from practices in the surveillance network of NIVEL-
PCD, using the old method (2002-2011) and the new method (2010-2012).
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Table 8.5 Estimated prevalence of patients with one or more episodes of genital herpes per 
100,000 population at GPs in the Netherlands by gender, based on extrapolation from 
practices in the surveillance network of NIVEL-PCD, using the old method (2002-2011) and the 
new method (2010-2012).
Men Women Total
  n/100,000 n/100,000 n/100,000
Old method
2002 36 72 54
2003 25 70 48
2004 35 85 60
2005 40 74 57
2006 27 96 62
2007 35 94 65
2008 51 111 81
2009 42 106 74
2010 47 93 70
2011 48 124 86
New method
2010 75 178 126
2011 65 178 122
2012 70 201 136
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9
Hepatitis B
9.1  Key points
• In 2013, the incidence of notified cases of acute hepatitis B was 0.8 per 100,000 inhabitants 
and was higher in men (1.2) than in women (0.4). In 2012, 1.0 per 100,000 inhabitants was 
notified with acute hepatitis B.
• The number of acute hepatitis B notifications decreased by 23 per cent compared with 2012 
due to a decrease in heterosexual transmission route (30 per cent), MSM transmission route 
(15 per cent) and a decrease in transmission by unknown route (27 per cent).
• Unprotected sexual contact remained the most important risk factor for acute hepatitis B 
(62%).
• At STI clinics, the number of hepatitis B diagnoses (acute and chronic) was 172 (44.8 per cent 
heterosexual men, 27.9 per cent MSM, 27.8 per cent women) in 2013. 
• At STI clinics, the positivity rate was higher among first generation migrants (1.0%) than 
among second generation migrants (0.1%) or among natives (0.1%). The highest positivity 
rates were observed among patients from Sub-Sahara African, Eastern European or Asian 
origin.
• Data from the screening of pregnant women showed an estimated prevalence of hepatitis B 
of 0.31% in 2012.
• Since the beginning of the programme in 2002, 18,374 commercial sex workers and 42,260 
MSM entered the vaccination programme for behavioural risk groups.
• Within the vaccination programme, 336 carriers of hepatitis B have been encountered 
among the commercial sex workers and MSM, and 8% of the participants have been in 
contact with hepatitis B previously.
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Figure 9.1 Incidence of acute hepatitis B per 100,000 inhabitants by region, the Netherlands, 
2013.
Incidence per 
100,000 inhabitants
1.0  - 2.0
2.0  - 3.5
0.0 - 1.0
(Source: RIVM-OSIRIS, notification data)
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9.2  Notification data: characteristics, risk groups and trends
Figure 9.2 Incidence of acute hepatitis B by gender, 1976–2013.
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Figure 9.3 Number of infections of acute hepatitis B by route of transmission, 2004–2013.
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Table 9.1 Proportion of acute hepatitis B cases by most common route of transmission, the 
Netherlands, 2013.
 Heterosexual 
contact
MSM Other
 (N=44) n (%)* (N=29) n (%)* (N=57) n (%)*
Infected abroad 8 (18.2) 2 (6.9) 11 (19.3)
Born abroad 9 (20.5) 5 (17.2) 16 (28.1)
Infected by casual partner 26 (59.1) 23 (79.3) –
Median age (+ range) 31.5 (14–68) 47 (24-84) 50 (11–80)
* Proportions per category can overlap, so percentages do not add up to 100%.
Note: Data of 2013 might be incomplete, because of delays in reporting (2013 data were collected on 
March 1-2014).
(Source: RIVM-OSIRIS, notification data)
9.3  Infectious hepatitis B diagnoses at the STI clinics
Table 9.2 Number of positive tests and persons tested for hepatitis B by age, gender and 
sexual preference, 2013.
Age (years) Heterosexual men MSM Women
n 
positive
N 
tested
n 
positive
N 
tested
n 
positive
N 
tested
≤ 14 0 3 0 1 0 45
15–19 1 1,225 1 425 6 3,419
20–24 13 7,414 2 1,723 9 12,218
25–29 24 5,516 9 1,677 11 6,293
30–34 13 2,698 7 1,418 4 2,258
35–39 7 1,365 6 1,238 9 1,070
40–44 11 1,040 6 1,236 4 821
45–49 1 722 10 1,071 3 596
50–54 2 503 3 713 1 329
≥ 55 5 509 4 800 0 220
Unknown 0 3 0 1 0 2
Total 77 20,998 48 10,303 47 27,271
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Figure 9.4 Percentage of positive tests for hepatitis B by age, gender and sexual preference, 
2013.
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Table 9.3 Number of positive tests and persons tested for hepatitis B by ethnicity, gender and 
sexual preference, 2013.
Ethnicity Heterosexual men MSM Women
n 
positive
N 
tested
n 
positive
N 
tested
n 
positive
N 
tested
The Netherlands 3 9,823 17 6,656 2 14,888
Turkey 5 766 1 164 1 419
North Africa/Morocco 3 1,355 2 181 3 777
Surinam 16 2,708 0 320 4 2,802
Netherlands Antilles/
Aruba
2 1,254 1 233 1 1,130
Sub-Saharan Africa 25 1,075 2 101 11 1,065
Eastern Europe 9 442 6 271 10 1,331
Latin America 3 483 5 395 1 955
Asia 9 1,399 11 620 9 1,788
Europe other 1 1,250 2 1,024 4 1,635
Else 1 198 1 166 0 291
Unknown 0 245 0 172 1 190
Natives 3 9,823 17 6,656 2 14,888
First generation migrants 66 5,181 29 2,419 38 5,655
Second generation migrants 8 5,704 1 1,032 6 6,490
Unknown 0 290 1 196 1 238
Total 77 20,998 48 10,303 47 27,271
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Figure 9.5 Percentage of positive tests for hepatitis B by ethnicity, gender and sexual 
preference, 2013.
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Table 9.4 Number and percentage of positive tests and total persons tested for hepatitis B by 
sexual behavioural characteristics, gender and sexual preference, 2013.
  Heterosexual men MSM Women
 n positive/N 
consultations
%
 
n positive/ N
consultations 
% n positive/N
consultations 
%
Number of partners in past 6 months 
0 partners 3/139 2.2 0/90 0.0 0/210 0.0
1 partner 23/3,445 0.7 4/1,168 0.3 21/7,279 0.3
2 partners 16/4,090 0.4 7/1,242 0.6 5/5,961 0.1
3 or more partners 35/13,169 0.3 34/7,640 0.4 15/13,091 0.1
Unknown 0/155 0.0 3/136 2.2 6/730 0.8
Condom use if last sexual contact was steady* 
No 38/7,532 0.5 12/3,116 0.4 26/11,901 0.2
Yes 10/1,922 0.5 2/949 0.2 4/2,232 0.2
Unknown 0/38 0.0 1/58 1.7 0/51 0.0
Condom use if last sexual contact was casual* 
No 17/7,784 0.2 17/3,663 0.5 6/8,851 0.1
Yes 11/3,426 0.3 12/2,203 0.5 10/3,770 0.3
Unknown 0/66 0.0 0/48 0.0 0/49 0.0
Previous GO/CT/syphilis in anamnesis 
No 72/18,287 0.4 38/8,664 0.4 40/23,610 0.2
Yes 3/1,545 0.2 7/1,229 0.6 2/2,566 0.1
Don’t know 1/606 0.2 1/266 0.4 1/539 0.2
Unknown 1/560 0.2 2/144 1.4 4/556 0.7
Previous HIV test 
No 37/9,613 0.4 7/2,419 0.3 21/10,868 0.2
Yes, positive 1/24 4.2 21/1,387 1.5 1/30 3.3
Yes, negative 39/11,119 0.4 20/6,409 0.3 24/15,983 0.2
Yes, result unknown 0/54 0.0 0/26 0.0 0/71 0.0
Unknown 0/188 0.0 0/62 0.0 1/319 0.3
CSW
No 77/20,908 0.4 45/10,036 0.4 35/25,094 0.1
Yes, in past 6 
months
0/70 0.0 3/220 1.4 12/2,146 0.6
Unknown 0/20 0.0 0/47 0.0 0/31 0.0
Client of CSW, men
No 65/17,996 0.4 47/9,608 0.5
Yes, in past 6 
months
12/2,931 0.4 1/334 0.3
Unknown 0/71 0.0 0/361 0.0   
136 Sexually transmitted infections, including HIV, in the Netherlands in 2013
Table 9.4 (continued) Number and percentage of positive tests and total persons tested for 
hepatitis B by sexual behavioural characteristics, gender and sexual preference, 2013.
  Heterosexual men MSM Women
 n positive/N 
consultations
%
 
n positive/ N
consultations 
% n positive/N
consultations 
%
Swinger**
No 31/9,757 0.3 12/2,994 0.4 20/10,659 0.2
Yes 1/378 0.3 0/270 0.0 1/586 0.2
Unknown 0/8 0.0 0/7 0.0 0/25 0.0
SES 
Very high 9/2,671 0.3 2/1,587 0.1 4/3,652 0.1
High 9/4,678 0.2 8/2,595 0.3 6/6,298 0.1
Medium 9/4,951 0.2 12/2,509 0.5 8/6,425 0.1
Low 20/4,040 0.5 13/1,825 0.7 11/4,954 0.2
Very low 17/2,778 0.6 4/801 0.5 4/2,988 0.1
Unkown 13/1,880 0.7 9/986 0.9 14/2,954 0.5
* Type of sexual contact was missing for 2% (n=911) of persons tested for hepatitis B.
** Voluntary question, answered by 42% (n=24,684) of persons tested for hepatitis B.
Table 9.5 Concurrent STI by gender and sexual preference among persons diagnosed with 
hepatitis B, 2013.
Concurrent infection Heterosexual men MSM Women
 (N=77) n (%) (N=48) n (%) (N=47) n (%)
Chlamydia 15 (19.5) 13 (27.1) 7 (14.9)
Gonorrhoea 1 (1.3) 7 (14.6) 0 (0.0)
Infectious syphilis 0 (0.0) 3 (6.3) 0 (0.0)
HIV newly diagnosed 0 (0.0) 2 (4.2) 0 (0.0)
Genital herpes 0 (0.0) 0 (0.0) 0 (0.0)
Genital warts 1 (1.3) 0 (0.0) 0 (0.0)
Hepatitis C 0 (0.0) 2 (4.2) 0 (0.0)
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9.4  Antenatal screening
Table 9.6 Hepatitis B prevalence estimates for pregnant women, based on test results of 
antenatal screening, 2006-2012.
Year No. of women 
screened
Positive result 
12 weeks test
Confirmed positive 
test results (%)
Prevalence estimate 
[min, max] 
2006 185,941 966 714 (74%) 0.4 [0.38–0.4]
2007 186,137 868 620 (71%) 0.34 [0.33–0.34]
2008 190,140 932 605 (65%) 0.33 [0.32–0.33]
2009 185,528 680 636 (94%) 0.36 [0.34–0.36]
2009/10 187,586 648 576 (90%) 0.31 [0.31–0.31]
2010/11 182,297 656 593 (91%) 0.33 [0.33–0.33]
2011# 88,489 284 0.32*
2012/13 173,880  536 0.31*
Footnote 1: Terminated pregnancies (induced or spontaneous) are excluded.
Footnote 2: Since 2009, time periods of data collection range from June to June the subsequent year
Footnote 3: For the prevalence calculation, we assumed that pregnant women with a first positive test 
result without a confirmation test would be as often positive as those with a confirmation test. In 
previous reports we showed a range of minimum to maximum prevalence. Minimum prevalence: 
number of confirmed positive test results divided by the total number of registered pregnant women; 
maximum prevalence: under the assumption that all pregnant women with a first positive test result 
without a confirmation test would also have a positive confirmation test.
* The prevalence was estimated using a conclusion made by the RIVM laboratory or, if this conclusion 
was unavailable, using the confirmation test. 
# Data from July-December 2011
(Source: Praeventis, RIVM)
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9.5  Blood donors
Figure 9.6 HBV incidence (per 100,000) among regular blood donors in the Netherlands, 
2000–2012.
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(Source: Sanquin)
9.6  Hepatitis B Vaccination programme for risk groups
Table 9.7 Number of vaccinated, chronically infected and immune participants of the HBV 
vaccination programme, 2002–2013.
  CSW MSM
First vaccination 18,374 42,260
Second vaccination 11,613 32,134
Third vaccination 7,897 26,416
HBV status at first consultation*   
Hepatitis B carrier (%) 139 (0.8) 197 (0.5)
Hepatitis B immune (%) 1,556 (8.5) 3,031 (7.2)
* During the consult of first vaccination all participants are tested serologically for markers of previous or 
current HBV infection.
Footnote: Not included in the table are heterosexuals (n=41,007) with multiple partners whom were 
included until October 2007, drug users (n=17,894), who were included until January 2012, and partici-
pants with unknown risk group (n=2,995).
139Sexually transmitted infections, including HIV, in the Netherlands in 2013
Table 9.8 Number and percentage of first HBV vaccinations per risk group and location of first 
vaccination, 2002-2013.
Location of first vaccination CSW MSM
 (N=18,374) n (%) (N=42,260) n (%)
STI clinic 2,794 (15.2) 12,188 (28.8)
Public health service* 11,471 (62.4) 26,151 (61.9)
Penitentairy institution 695 (3.8) 151 (0.4)
MSM location 56 (0.0) 2,051 (0.0)
Drug location 33 (0.2) 111 (0.3)
CSW location 3,228 (17.6) 10 (0.0)
Other 97 (0.5) 1,598 (3.8)
* The number of HBV vaccinations given at public health services can also consist of vaccinations given at 
an STI clinic. In a number of regions the STI clinic and the PHS work closely together.
Figure 9.7 Number of persons entering the HBV vaccination programme, 2002–2013.
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10
Hepatitis C
10.1  Key points
• In 2013, the total number of acute HCV notifications was 62 in the Netherlands, and 
increased with 72% compared with 2012 (n =36). 
• Unprotected sexual contact between men remained the most important route of transmis-
sion for acute hepatitis C (82%). 
• Of all HCV positive MSM (n=51) notified in 2013, 71% (n=36) were HIV positive.
• At STI clinics, 36 cases of hepatitis C were diagnosed, of which 94% (n=34) in MSM.
• HCV has not been detected in blood donors since 2008.
• A national population-based cross-sectional serosurvey (PIENTER-2) performed in 2006-
2007, resulted in a weighted national HCV seroprevalence of 0.30% (95% confidence interval 
0.05–0.55%). About 70% of the HCV positive individuals found were born in an HCV-
endemic country 8.
8 Vriend HJ, Op de Coul EL, van de Laar TJ, Urbanus AT, van der Klis FR, Boot HJ. Hepatitis C virus seroprevalence in The Netherlands. Eur J Public Health. 2012 
Mar 29. [Epub ahead of print]
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10.2  Notification data: characteristics, risk groups and trends
Figure 10.1 Number of infections of acute HCV infections by route of transmission, 
2004–2013.
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10.3  Blood donors
Figure 10.2 HCV incidence (per 100,000) among regular blood donors in the Netherlands, 
2000–2012.
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(Source: Sanquin)
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11 
General conclusions and 
recommendations
To promote sexual health and to control transmission of STI, a policy of proximity and easy 
access to STI care has been implemented in the Netherlands. The surveillance system is 
focused on trends among high-risk groups, as changes in the occurrence of STI and HIV are 
expected to be most visible in these groups. The results of the surveillance data from 2013 
show that access to STI testing further improved (viz. the continued rise in consultations at STI 
clinics), while the overall positivity stabilised, which indicates an efficient control approach. 
The continuing high STI positivity rate indicates that special attention should be paid to the 
challenges of STI control. 
An important feature of effective control efforts is early detection of STI and HIV, which will 
result in individual health gains by preventing or reducing morbidity following adequate 
treatment. In addition, early detection may result in public health gains by preventing onward 
transmission among the population; thereby leading to less exposure to STI. Early detection 
and treatment of STI and HIV should remain an important public health priority. However, 
repeated population based studies are necessary to confirm the effect on transmission.
Groups that are at high-risk for STI, as reflected in their higher positivity rates, include MSM (in 
particular HIV infected MSM), specific migrant populations, and young people (under 25 years 
of age). High-risk behaviour, such as no condom use and more than 3 sex partners in the 
preceding six months, has not diminished among STI clinic attendees. This suggests that 
innovative approaches are needed to ensure that people in high-risk groups are able to 
effectively reduce their sexual risk and improve their sexual health. At the same time, testing 
and treatment strategies need to be optimised to provide optimal benefit from control efforts 
for the largest number of people, and to prevent the overburdening of curative services. For 
the latter, since 2012, STI clinics initially offered young heterosexuals with no additional risk 
factors a chlamydia test only, rather than the STI testing package of chlamydia, gonorrhoea, 
syphilis and HIV that is the minimum for other high-risk attendees. Data from 2013 show that 
this policy change is efficient, as among 1,273 young people without additional risk factors but 
who had a chlamydia infection, only 14 gonorrhoea infections were diagnosed but no syphilis 
or HIV. In addition, this national policy change of offering only an initial chlamydia test has led 
to a substantial reduction in test costs 9.  The policy measure would be even more efficient if a 
combination test for chlamydia and gonorrhoea would be applied in the future. 9 Moreover, 
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providing a chlamydia test only enables the development of innovative testing opportunities, 
such as home test kits available via the Internet. Such low threshold testing opportunities may 
reach potentially hidden at-risk populations and individuals who otherwise would not have 
sought STI testing. 
As in previous years, and as in many other countries, Chlamydia trachomatis remains the most 
commonly reported bacterial STI, both among high-risk groups at STI clinics and among the 
general population, covered by data from general practice surveillance. While a decrease in 
chlamydia positivity rate was observed in heterosexual men and MSM tested at STI clinics in 
2013, and the number of infections reported in the laboratory surveillance stabilised after more 
than 10 years of steady increase, the estimated chlamydia prevalence at general practices (GPs) 
increased. These differences can be partly explained through changes in policies (higher testing 
volumes at STI clinics due to chlamydia-only policy in low risk <25 years) and in surveillance 
(NIVEL Primary Care Database), but this nevertheless implies that transmission is still ongoing 
in a wide segment of the sexually active population. To decrease chlamydia prevalence, 
additional efforts or interventions could be implemented. First, individuals at risk of STI and 
HIV should be encouraged to reduce sexual risk behaviour, and to undergo regular tests 
enabling prompt treatment. Second, GP awareness of the high chlamydia prevalence could be 
increased, as they detect and prescribe treatment for the majority of chlamydia infections. 
Third, GPs could be encouraged to offer opportunistic screening more commonly to young 
people at risk. Among individuals at risk for STI/HIV, a barrier for testing at GPs could be the 
price of a test which often is covered by their own insurance risk fee. Fourth, case management 
could be improved by emphasising the need for partner notification and treatment as a 
standard topic in any STI treatment consultation. At the same time, additional research is 
essential to optimise chlamydia control efforts by improved targeting of those most at risk. A 
high rate of chlamydia positivity six months after an initial positive chlamydia test suggests 
that some infections may not be cleared or reinfections may be easily acquired.10 Fortunately, 
results from the chlamydia reference laboratory show that, so far, incidental reports of 
treatment failure and diagnostic escape mutants (such as the Swedish variant) are not threate-
ning overall control efforts. Other ongoing research aims to improve understanding of the 
behavioural, immunological and genetic factors that increase risks of developing long-term 
sequelae of chlamydia (PID, subfertility, ectopic pregnancies).
Infections with gonorrhoea occurred mainly in MSM and the positivity rate was stable in 2013 
compared to 2012. Reporting rates of gonorrhoea increased substantially in the general 
practice surveillance network; a change in the joining practices and in case definition notwit-
hstanding, the increase has taken quite alarming dimensions, especially in women. Alertness is 
needed to ensure that gonorrhoea transmission does not become more widespread among 
other groups such as young heterosexuals. Close surveillance of gonorrhoea trends is of 
particular importance, as the threat of drug-resistant gonorrhoea is becoming ever more real, 
since the first treatment failures with the only available treatment option (third-generation 
9  A.W.M. Suijkerbuijk. E.A.B Over, F.D.H. Koedijk et al. Doelmatiger testbeleid van soa-poliklinieken GGD. Ned Tijdschr Geneeskd 2014;158:A6980
10 Dukers-Muijrers NH, Speksnijder AG, Morré SA, et al. Detection of anorectal and cervicovaginal Chlamydia trachomatis infections following azithromycin treatment: 
prospective cohort study with multiple time-sequential measures of rRNA, DNA, quantitative load and symptoms. PLoS One. 2013 Nov 20;8(11):e81236.
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cephalosporin) has already been reported in European patients. In 2013, the Centre for Disease 
Control indicated drug-resistant gonorrhoea as one of the three most urgent threats. So far, no 
resistance to ceftriaxone, a third-generation cephalosporin that has been the first-choice 
medication since 2004, was found in the Netherlands. There is room for improvement in 
prescribing this first choice medication among GPs; hopefully the renewed version of STI 
guidelines for GPs will facilitate this.11  Furthermore, the declining number of diagnostic 
cultures and a lack of standardised diagnostic methods in laboratories outside the specialised 
STI settings are also a concern, as these may obscure adverse trends.
The majority of new HIV diagnoses occurred among MSM, in particular among those with 
high-risk behaviour. This is reflected in high STI coinfection rates in this group compared to 
other high-risk groups. The HIV positivity rate at STI clinics has been declining over the past 
years, which is encouraging. The decreasing proportion of low CD4 counts (<350) in newly 
diagnosed HIV-positive people indicates that HIV infections are being diagnosed at an earlier 
stage, which is also reflected by the increasing number of STI clinic attendees who reported a 
previous HIV test. Nevertheless, heterosexuals are diagnosed in a later phase than MSM, 
especially those diagnosed at GPs or in the hospital. To test for recent HIV infections, the 
anti-HIV avidity assay was implemented at all STI clinics from January 2014. The implementa-
tion of this so-called RITA (Recent Infections Testing Algorithm) surveillance will provide 
additional insights into recent HIV and established HIV infections, trends in recent infections, 
and differences between risk groups.12  
Apart from the prevalent STIs in most high-risk groups in general and in MSM in particular, a 
much higher prevalence of LGV and hepatitis C is observed among HIV-infected patients. 
Mathematical and economic modelling indicates that routine STI screening can be cost-effec-
tively combined with treatment of HIV-infected MSM 13. At the same time, efforts to reduce the 
estimated large percentage of HIV-infected people not yet aware of their infection or not yet 
reported into care, need to continue. Results of a partner notification project at STI clinics 
showed that contacting partners of MSM is hampered by the anonymous nature of many 
contacts14. At GPs, risk groups should be identified better (by asking questions on sexual 
behaviour and risks) and GPs (or their assistants) should be encouraged to be more proactive 
in offering an HIV test to those at risk and those having HIV indicator diseases. Thus, a diffe-
rential approach towards different groups at risk of HIV and other STI is warranted. 
In contrast to the number of acute hepatitis C notifications, the number of acute hepatitis B 
notifications has decreased. A modelling study showed that hepatitis B vaccination of MSM in 
the Netherlands has had a substantial impact in reducing hepatitis B incidence. However, there 
are large regional differences in hepatitis B incidence that might suggest regional variation in 
the vaccination coverage. Gaining more insights into regional differences in STI/HIV could be 
11 van Bergen JEAM, Dekker JH, Boeke  AJP, et al. NHG-Standaard ‘Het soa-consult’ (eerste herziening). Huisarts Wet 2013; 56: 450-463.
12 Sane J, Heijman T, Hogema B, et al. Sex Transm Infect.Published Online First: 28-01-2014. doi:10.1136/sextrans-2013-051420. Identifying recently acquired HIV 
infections among newly diagnosed men who have sex with men attending STI clinics in The Netherlands.
13 Vriend HJ, Lugnér AK, Xiridou M, et al. Sexually transmitted infections screening at HIV treatment centers for MSM can be cost-effective. AIDS. 2013 Sep 
10;27(14):2281-90.
14 van Aar F, Schreuder I, van Weert Y, et al. Current practices of partner notification among MSM with HIV, gonorrhoea and syphilis in the Netherlands: an urgent 
need for improvement. BMC Infect Dis 2012, 12:114
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beneficial for STI/HIV prevention and control, as successful regional prevention and control 
activities can be implemented.
STI clinics aim to provide care for those at high risk, in addition to the regular integrated care 
provided by GPs. Indeed, highly prevalent STI, i.e. chlamydia, human papillomavirus (resulting 
e.g. in genital warts) and HSV (resulting in e.g. genital ulcers), remain much more commonly 
diagnosed by GPs than at STI clinics. Other STI, such as gonorrhoea, syphilis and HIV, are 
currently concentrated in high-risk groups, with limited transmission among the general 
population. These STI are more commonly diagnosed at STI clinics. The role of GPs can be 
strengthened by improved awareness of the need for testing specific patient groups for STI 
following the updated primary care STI guidelines, as well as identification of opportunities to 
promote sexual health and prevent STI transmission. Collaboration between regional STI 
clinics and medical microbiological laboratories can ensure that early warning signs, not (yet) 
visible in surveillance trends, are identified at an early stage. Improved professional collabora-
tion is already apparent in the coordinated revision of STI guidelines by medical specialists, 
GPs and public health professionals. The integration of curative and preventive control 
activities in STI clinics has been strengthened by the development of a single quality control 
guideline which forms the basis for interdisciplinary visitations.
Sexual risks and (new) STIs can emerge among many groups, not just the currently well-known 
high-risk groups already targeted for control efforts. NGOs are particularly well suited to the 
task of liaison with target groups and ensuring that they have access to information and care, 
and that their needs are met. Coordinated online efforts to reach these groups and provide 
them with tailored information on sexual health and STI prevention and control need to be 
strengthened and will become even more important in the future. The persistent high-risk 
behaviour of many sexually active adolescents and adults necessitates high vigilance towards 
possible transmission of STI like gonorrhoea, outside the recognised target groups. In addi-
tion, treatment failure due to poor adherence, inadequate testing, inappropriate therapy or 
antimicrobial resistance, can result in deterioration of control efforts. With shrinking budgets 
and less possibilities to expand the control of STI transmission within both high and (tradition-
ally) low-risk groups, rigorous surveillance using standardised protocols remains a cornerstone 
in the effort to enable actions to be taken as soon as the (re)emergence of STI is feared.
Recommendations:
• Maintain integrated surveillance of STIs and STI risks among high-risk groups.
• Strengthen intersectoral collaboration between those who provide sexual health care in STI 
clinics and in regular care (HTCs, GPs and related medical specialists), between NGOs and 
care providers, and between laboratories and clinicians.
• Maintain a strong multisectoral basis for STI control to facilitate easy access to care and 
testing, rapid and reliable results, and effective treatment and prevention including e-health.
• Support efforts to gain more insights into regional differences in STI.
• Strengthen the implementation of STI guidelines by health care professionals.
• Support efforts to gain more insights into the long-term sequelae of chlamydia infection.
• Stimulate systematic culturing of gonorrhoea diagnosed among high-risk groups to prevent 
the transmission of pan-drug-resistant strains.
• Stimulate efforts to integrate STI screening in HIV care.
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Appendix A      List of abbreviations
ACS Amsterdam Cohort Studies
AIDS Acquired Immune Deficiency Syndrome
ATHENA AIDS Therapy Evaluation in the Netherlands
CIb Centrum Infectieziektebestrijding, Centre for Infectious Disease and Control
CSI Chlamydia Screening Implementation
CSW Commercial Sex Worker
DU Drug Users
ECDC European Centre for Disease Prevention and Control
GP General Practitioner
GRAS Gonococcal Resistance to Antimicrobials Surveillance programme
HAART Highly active anti-retroviral therapy
HBV Hepatitis B virus
HCV Hepatitis C virus
HIV  Human Immunodeficiency virus
HPV Human papillomavirus
HSV Herpes simplex virus
IDU Intravenous Drug Users
IGZ Inspectorate of Health
LGV Lymphogranuloma venereum
LIS Laboratory for Infectious Disease and Screening
LINH Landelijk Informatienetwerk Huisartsen, Information Network of 
 General Practice
MIC Minimum Inhibitory Concentration
MSM Men who have sex with men
NIVEL Nederlands Instituut voor onderzoek van de Gezondheidszorg, 
 Netherlands Institute for Health Services Research
NPCD NIVEL Primary Care Database
PHS Public Health Service
PID Pelvic Inflammatory Disease
RIVM Rijksinstituut voor Volksgezondheid en Milieu, National Institute 
 for Public Health and the Environment
SHM Stichting HIV Monitoring
SOAP Online STI registration system
STI Sexually Transmitted Infection
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Appendix B      National Surveillance of STI clinics
Coordinating STI clinics
GGD Amsterdam:   A. Hogewoning 
GGD Haaglanden:   M. Somsen
GGD Groningen:   F. de Groot
GGD Hart voor Brabant:   J.C.A.M. van de Sande
  H. van Kruchten
GGD Gelderland-Zuid:   A. van Daal
  R. Koene
GGD Rotterdam-Rijnmond  V. Wieërs
  H. Götz
  B. Nuradini
GGD Regio Utrecht:   M. Langevoort
  V. Sigurdsson
GGD Zuid Limburg:   C.J.P.A. Hoebe
  E.J.W.M. Niekamp
Regional STI clinics
GGD Brabant Zuid-Oost   
GGD Drenthe    
GGD Flevoland    
GGD Fryslân    
GGD Gelderland-Zuid    
GGD Hollands-Midden    
GGD Hollands Noorden   
GGD IJsselland 
GGD Kennemerland
GGD Limburg-Noord 
GGD Midden-Nederland
GGD Noord- en Oost Gelderland
GGD Rivierenland 
GGD Twente         
GGD West-Brabant       
GGD Zaanstreek-Waterland  
GGD Zeeland    
GGD Zuid-Holland Zuid   
Veiligheids- en Gezondheidsregio Gelderland-Midden    
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Laboratories
Academisch Ziekenhuis Maastricht      
Albert Schweitzer Ziekenhuis Dordrecht     
Amphia Ziekenhuis Breda
Canisius Wilhelmina Ziekenhuis Nijmegen    
Centraal Bacteriologisch en Serologisch laboratorium Hilversum
Diagnostiek voor U Eindhoven
Erasmus MC Rotterdam
Gelre Ziekenhuizen Apeldoorn
Groene Hart Ziekenhuis Gouda
Isala klinieken Zwolle
Izore, Centrum Infectieziekten Friesland
Jeroen Bosch Ziekenhuis ’s-Hertogenbosch
Laboratoria Pathologische Anatomie en Medische Microbiologie Veldhoven
Laboratorium Microbiologie Twente Achterhoek
Laboratorium voor Infectieziekten Groningen   
Leiden Universitair Medisch Centrum
Meander Medisch Centrum Amersfoort
Medisch Centrum Haaglanden Den Haag
Medisch Centrum Alkmaar
Medisch Centrum Spijkenisse
Slingeland Ziekenhuis Doetinchem
St. Elisabeth Ziekenhuis Tilburg
Streeklaboratorium voor de Volksgezondheid Amsterdam
Streeklaboratorium voor de Volksgezondheid Deventer
Streeklaboratorium voor de Volksgezondheid Haarlem
Laboratorium voor medische microbiologie & immunologie Admiraal de Ruyter ziekenhuis 
Goes
Universitair Medisch Centrum St. Radboud 
Universitair Medisch Centrum Utrecht
Zaans Medisch Centrum Zaandam
Laboratorium pathologie (ADRZ) Terneuzen
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Appendix C      Stichting HIV Monitoring
Within the framework of the Stichting HIV Monitoring, a substantial number of professionals 
are participating:
Treating physicians (*Site coordinating physicians)
Medisch Centrum Alkmaar, Alkmaar: Drs. G. van Twillert*, Drs. W. Kortmann*, Dr. J.W.T. 
Cohen Stuart, Dr. B.M.W. Diederen 
Flevoziekenhuis, Almere: Dr. J. Branger* 
Academic Medical Center of the University of Amsterdam, Amsterdam: Prof. J.M. Prins*, 
Prof. T.W. Kuijpers, Dr. H.J. Scherpbier, Dr. J.T.M. van der Meer, Dr. F.W.M.N. Wit, Dr. M.H. 
Godfried, Prof. P. Reiss, Prof. T. van der Poll, Dr. F.J.B. Nellen, Prof. J.M.A. Lange, Dr. S.E. 
Geerlings, Dr. M. van Vugt, Drs. D. Pajkrt, Drs. J.C. Bos, Drs. M. van der Valk, Drs. M.L. Grijsen, 
Dr. W.J. Wiersinga, Dr. A. Goorhuis, Dr. J.W.R. Hovius 
Onze Lieve Vrouwe Gasthuis, Amsterdam: Prof. K. Brinkman*, Dr. W.L. Blok, Dr. P.H.J. Frissen, 
Drs. W.E.M. Schouten, Drs. G.E.L. van den Berk 
Sint Lucas Andreas Ziekenhuis, Amsterdam: Dr. J. Veenstra*, Dr. K.D. Lettinga 
Slotervaartziekenhuis, Amsterdam: Dr. J.W. Mulder*, Dr. S.M.E. Vrouenraets, Dr. F.N. Lauw
Stichting Medisch Centrum Jan van Goyen, Amsterdam: Drs. A. van Eeden*, Dr. D.W.M. 
Verhagen 
VU Medisch Centrum, Amsterdam: Dr. M.A. van Agtmael*, Dr. R.M. Perenboom, Drs. F.A.P. 
Claessen, Dr. M. Bomers, Dr. E.J.G. Peters
Rijnstate, Arnhem: Dr. C. Richter*, Dr. J.P. van der Berg, Dr. E.H. Gisolf 
HagaZiekenhuis, Den Haag: Dr. E.F. Schippers*, Dr. C. van Nieuwkoop, Drs. E.P. van Elzakker
Medisch Centrum Haaglanden, Den Haag: Dr. E.M.S. Leyten*, Dr. L.B.S. Gelinck 
Catharina Ziekenhuis, Eindhoven: Drs. M.J.H. Pronk*, Dr. H.S.M. Ammerlaan 
Medisch Spectrum Twente, Enschede: Drs. G.J. Kootstra*, Drs. C.E. Delsing
Universitair Medisch Centrum Groningen, Groningen: Drs. H.G. Sprenger*, Dr. E.H. 
Scholvinck, Drs. S. van Assen, Dr. W.F.W. Bierman, Drs. K.R. Wilting, Dr. Y. Stienstra 
Kennemer Gasthuis, Haarlem: Dr. R. Soetekouw*, Prof. R.W. ten Kat 
Medisch Centrum Leeuwarden, Leeuwarden: Dr. M.G.A. van Vonderen*, Drs. D.P.F. van Houte 
Leids Universitair Medisch Centrum, Leiden: Dr. F.P. Kroon*, Prof. J.T. van Dissel, Dr. S.M. 
Arend, Dr. M.G.J. de Boer, Drs. H. Jolink, Dr. H.J.M. ter Vollaard, Drs. M.P. Bauer
MC Zuiderzee, Lelystad: Dr. S. Weijer*, Dr. R. el Moussaoui            
Academisch Ziekenhuis Maastricht, Maastricht: Dr. S. Lowe*, Dr. G. Schreij, Dr. A. Oude 
Lashof, Dr. D. Posthouwer 
Universitair Medisch Centrum Sint Radboud, Nijmegen: Dr. P.P. Koopmans*, Dr. M. Keuter, 
Dr. A.J.A.M. van der Ven, Dr. H.J.M. ter Hofstede, Dr. A.S.M. Dofferhoff, Dr. A. Warris, Dr. R. van 
Crevel
Erasmus Medisch Centrum, Rotterdam: Dr. M.E. van der Ende*, Dr. T.E.M.S. de Vries-Sluijs, 
Dr. C.A.M. Schurink, Dr. J.L. Nouwen, Prof.dr. A. Verbon, Drs. B.J.A. Rijnders, Dr. E.C.M. van 
Gorp, Drs. M. van der Feltz
Erasmus Medisch Centrum–Sophia, Rotterdam: Dr. G.J.A. Driessen, Dr. A.M.C. van Rossum 
Maasstad Ziekenhuis, Rotterdam: Dr. J.G. den Hollander*, Dr. K. Pogany 
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St Elisabeth Ziekenhuis, Tilburg: Dr. M.E.E. van Kasteren*, Dr. A.E. Brouwer 
Universitair Medisch Centrum Utrecht, Utrecht: Prof. A.I.M. Hoepelman*, Dr. T. Mudrikova, 
Dr. M.M.E. Schneider, Dr. P.M. Ellerbroek, Dr. J.J. Oosterheert, Dr. J.E. Arends, Dr. M.W.M. 
Wassenberg, Dr. R.E. Barth 
Wilhelmina Kinderziekenhuis, UMCU, Utrecht: Dr. S.P.M. Geelen, Dr. T.F.W. Wolfs, Dr. L.J. Bont 
Admiraal De Ruyter Ziekenhuis, Vlissingen: Drs. M. van den Berge*, Drs. A. Stegeman 
Isala, Zwolle: Dr. P.H.P. Groeneveld*, Drs. J.W. Bouwhuis 
Sint Elisabeth Hospitaal, Willemstad, Curaçao: Dr. C. Winkel, Drs. F. Muskiet, Drs. Durand, 
Drs. R. Voigt
Virologists/Microbiologists 
Medisch Centrum Alkmaar, Alkmaar: Dr. F. Vlaspolder, Dr. B.M.W. Diederen, Dr. J.W.T. Cohen 
Stuart, Dr. W.A. van der Reijden
Academic Medical Center of the University of Amsterdam, Amsterdam: Dr. N.K.T. Back, Prof.
dr. B. Berkhout, Dr. M.T.E. Cornelissen, Dr. S. Jurriaans,  Dr. H.L. Zaaijer, Dr. C.J. Schinkel
Onze Lieve Vrouwe Gasthuis, Amsterdam: Dr. A.P. van Dam, Dr. M.L. van Ogtrop
Sanquin Bloedvoorziening, Amsterdam: Dr. M. Koot 
Sint Lucas Andreas Ziekenhuis, Amsterdam:  Dr. M. Damen, Dr. P.G.H. Peerbooms  
Slotervaartziekenhuis, Amsterdam: Dr. C. Roggeveen, Dr. P.H.M. Smits
VU Medisch Centrum, Amsterdam: Dr. C.W. Ang, Dr. A.M. Pettersson, Prof. C.M.J.E. 
Vandebroucke-Grauls
Microbiologisch en Immunologisch Laboratorium, Arnhem: Drs. R.W. Bosboom, Dr. M.A. 
Schouten 
Rijnstate, Arnhem: Dr. C.M.A. Swanink, R. Tiemessen
HagaZiekenhuis (location Leyenburg), Den Haag: Dr. P.F.H. Franck
Medisch Centrum Haaglanden (location Westeinde), Den Haag: Drs. C.L. Jansen, J.A.E.M. 
Mutsaers
PAMM, Veldhoven / Catharina Ziekenhuis, Eindhoven: Drs. A.R. Jansz, Dr. J. Tjhie
Laboratorium voor Infectieziekten, Groningen: Dr. C.A. Benne 
Universitair Medisch Centrum Groningen, Groningen: Prof. H.G.M. Niesters, Dr. A. Riezebos-
Brilman, Dr. C. van Leer-Buter
Kennemer Gasthuis, Haarlem: Dr. R. Jansen, Dr. W.A. van der Reijden
Streeklaboratorium Kennemerland, Haarlem: Dr. D. Veenendaal
Izore, Centrum Infectieziekten Friesland, Leeuwarden: Drs. J. Weel 
Leids Universitair Medisch Centrum, Leiden: Dr. E.C.J. Claas, Prof. A.C.M. Kroes 
Academisch Ziekenhuis Maastricht, Maastricht: Dr. I.H. Loo, Prof. P.H.M. Savelkoul
Universitair Medisch Centrum Sint Radboud, Nijmegen: Dr. F.F. Stelma
Erasmus Medisch Centrum, Rotterdam: Prof. C.A.B. Boucher, Prof. A.D.M.E. Osterhaus, Dr. M. 
Schutten
Maasstad Ziekenhuis, Rotterdam: Dr. O. Pontesilli
St Elisabeth Ziekenhuis, Tilburg: Dr. A.G.M. Buiting, Dr.P.J. Kabel, P. van de Korput, Dr. J.H. 
Marcelis
Universitair Medisch Centrum Utrecht, Utrecht: Dr. R. Schuurman, Dr. F. Verduyn-Lunel, Dr. 
A.M.J. Wensing
Admiraal De Ruyter Ziekenhuis, Goes: Dr. L. Sabbe
Isala Klinieken, Zwolle: Dr. P. Bloembergen, Dr. G.J.H.M. Ruijs, Dr. M.J.H.M. Wolfhagen
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Pharmacologists 
Slotervaart Ziekenhuis, Amsterdam: Prof. J.H. Beijnen, Dr. A.D.R. Huitema
Universitair Medisch Centrum St. Radboud, Nijmegen: Prof. D.M. Burger
Erasmus Medisch Centrum, Rotterdam: Dr. D.A.M.C. van de Vijver
Universitair Medisch Centrum Utrecht, Utrecht: Dr. I. Wilting, Prof. A.C.G. Egberts, Dr. E.M. 
van Maarseveen
Leids Universitair Medisch Centrum, Leiden: Prof. H.J. Guchelaar 
Medisch Spectrum Twente, Enschede: Dr. K.L.L. Movig
HIV Treatment Centres 
Medisch Centrum Alkmaar, Wilhelminalaan 12, 1815 JD Alkmaar
Flevoziekenhuis, Hospitaalweg 1, 1315 RA  Almere
Academic Medical Center of the University of Amsterdam, Meibergdreef 9, 1105 AZ 
Amsterdam
Emmakinderziekenhuis, AMC Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam
Onze Lieve Vrouwe Gasthuis, 1e Oosterparkstraat 179, 1091 HA Amsterdam
Sint Lucas Andreas Ziekenhuis, Postbus 9243, 1006 AE Amsterdam
Slotervaartziekenhuis, Louwesweg 6, 1066 CE Amsterdam
Stichting Medisch Centrum Jan van Goyen,  Jan van Goyenkade 1, 1075 HN Amsterdam
VU Medisch Centrum, De Boelelaan 1117, 1081 HV Amsterdam
Rijnstate, Wagnerlaan 55, 6815 AD Arnhem
HagaZiekenhuis (location Leyenburg), Leyweg 275, 2545 CH Den Haag
Medisch Centrum Haaglanden (location Westeinde), Lijnbaan 32, 2512 VA Den Haag
Catharina Ziekenhuis, Postbus 1350, 5602 ZA Eindhoven
Medisch Spectrum Twente, Postbus 50, 7500 KA Enschede
Universitair Medisch Centrum Groningen, Oostersingel 59, 9715 EZ Groningen
Universitair Medisch Centrum Groningen – Beatrix Kliniek, Oostersingel 59, 9715 EZ 
Groningen
Kennemer Gasthuis (location EG), Boerhaavelaan 22, 2000 AK Haarlem
Medisch Centrum Leeuwarden (location Zuid), H. Dunantweg 2, 8934 AD Leeuwarden
Leids Universitair Medisch Centrum, Rijnsburgerweg 10, 2333 AA Leiden
MC Zuiderzee, Ziekenhuisweg 100, 8233 AA, Lelystad (from 1 January, 2012)
Academisch Ziekenhuis Maastricht, P. Debyelaan 25, 6229 HX Maastricht
Universitair Medisch Centrum St. Radboud, Postbus 9101, 6500 HB Nijmegen
Erasmus MC, Dr. Molewaterplein 40, 3015 GD Rotterdam
Erasmus MC - Sophia, Dr. Molenwaterplein 40, 3015 GD Rotterdam
Maasstad Ziekenhuis (location Clara), Olympiaweg 350, 3078 HT Rotterdam
St Elisabeth Ziekenhuis, Hilvarenbeekseweg 60, 5022 GC Tilburg
Universitair Medisch Centrum Utrecht, Heidelberglaan 100, 3584 CX Utrecht
Wilhelmina Kinderziekenhuis Utrecht, Postbus 85090, 3508 AB Utrecht
Admiraal De Ruyter Ziekenhuis, Koudekerkseweg 88, 4382 EE Vlissingen
Isala, Dokter van Heesweg 2, 8025 AB Zwolle
St. Elisabeth Hospitaal, Breedestraat 193 (0), Willemstad, Curaçao
Stichting Rode Kruis Bloedbank, Huize Batavia, Pater Euwensweg 36, Willemstad, Curaçao
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Other institutions 
Sanquin Bloedvoorziening, Plesmanlaan 125, 1066 CX Amsterdam
Laboratorium Mircobiologie Twente Achterhoek, Burg. Edo Bergsmalaan 1, 7512 AD 
Enschede
Laboratorium voor Infectieziekten, Van Swietenlaan 2, 9728 NZ Groningen
Streeklaboratorium Kennemerland, Boerhaavelaan 26, 2035 RE Haarlem
Izore, Centrum Infectieziekten Friesland, Postbus 21020, 8900 JA Leeuwarden
Governing Board SHM 
Dr. F.P. Kroon (Chair), NVHB nominated 
Affiliation: Leiden University Medical Centre, Leiden
Dr. J.S.A. Fennema (Secretary), GGD Nederland nominated 
Affiliation: GGD Amsterdam, Amsterdam
Prof. K. Stronks (Ad Interim Treasurer, from 1 December 2012), AMC-UvA nominated 
Affiliation: Academic Medical Centre of the University of Amsterdam, Amsterdam 
Dhr. L.J.M. Elsenburg, HIV Vereniging Nederland nominated 
Affiliation: VU Medisch Centrum, Amsterdam
Dr. R.J.M. Hopstaken, NFU nominated 
Affiliation: Academic Medical Centre of the University of Amsterdam, Amsterdam
Drs. P.E. van der Meer, NFZ nominated 
Affiliation: Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands 
Drs. M.I. Verstappen, AGIS nominated 
Affiliation: AGIS, Amersfoort
Advisory Board SHM 
Prof. J.M.A. Lange (Chair), AMC, Dept. of Global Health; AIGHD, Amsterdam
Prof. Sir R.M. Anderson, Imperial College, Faculty of Medicine, Dept. of Infectious Disease 
Epidemiology, London, UK
Prof. G. Chene, Université Victor Segalen, Bordeaux, France (from 1 January 2013)
Prof. dr. M. Egger, University of Bern, Switzerland; University of Bristol, UK
Dr. S.E. Geerlings, AMC, Dept. of Internal Medicine, Amsterdam
Prof. D.R. Kuritzkes, Brigham and Women’s Hospital, Section of Retroviral Therapeutics, 
Boston, MA, USA
Mr. C. Rümke, HIV Vereniging Nederland, Amsterdam
Working Group SHM - Members 
Dr. M.E. van der Ende (Chair), Erasmus MC, Dept. of Internal Medicine, Rotterdam
Dr. K. Boer, AMC, Dept. of Obstretrics/Gynaecology, Amsterdam 
Prof. C.A.B. Boucher, Erasmus MC, Dept. of Internal Medicine, Rotterdam
Dr. F.C.M. van Leth, KNCV Tuberculosis Foundation, The Hague; AIGHD Amsterdam
Dr. W.M.C. Mulder, HIV Vereniging Nederland, Amsterdam
Working Group SHM - Reviewers  
Dr. N.K.T. Back, AMC, Clinical Virology Laboratory, Amsterdam
Prof. K. Brinkman, OLVG, Dept. of Internal Medicine, Amsterdam
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M. van den Akker 
Y.M. Bakker
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